最新ガイドラインに基づく　神経疾患　診療指針　2021-’22

出版社： 総合医学社
著者：
発行日： 2021-05-30
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 9784883787418
電子書籍版： 2021-05-30 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

13,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

13,200 円(税込)

購入する

商品紹介

神経領域における診療ガイドラインに基づく医療が可能な疾患を網羅し、初版同様、診療ガイドラインは作成されていないものの日常の診療で頻度が高く欠くことのできない重要な疾患も掲載。疾患の概要・病態、検査と診断、具体的な処方例を含めた治療の実際、general practitionerとして活躍されている読者をも想定して専門医へ紹介するタイミング、および専門医からのアドバイス、などを簡潔にまとめました。

目次

  • 1．脳血管障害
    アテローム血栓性脳梗塞
    心原性脳塞栓症
    ラクナ梗塞
    一過性脳虚血発作（TIA）
    無症候性脳梗塞
    脳動脈解離
    脳出血
    くも膜下出血
    もやもや病（ウイリス動脈輪閉塞症）
    脳静脈洞血栓症
    CADASIL，CARASIL
    高血圧性脳症
    巨細胞性動脈炎
    抗リン脂質抗体症候群

    2．認知症を主とする疾患
    アルツハイマー病
    レビー小体型認知症
    前頭側頭型認知症（FTD）
    血管性認知症
    正常圧水頭症

    3．錐体外路症状を主とする疾患
    パーキンソン病
    進行性核上性麻痺（PSP）
    ハンチントン病
    本態性振戦
    ミオクローヌス，アテトーゼ，バリズム，コレア

    4．脊髄小脳変性症・多系統萎縮症
    脊髄小脳変性症・多系統萎縮症

    5．脊髄症状を主とする疾患
    脊髄腫瘍と類似疾患
    OPLL/OLF
    筋萎縮性側索硬化症（運動ニューロン疾患）
    球脊髄性筋萎縮症（Kennedy-Alter-Sung 症候群）
    脊髄血管障害
    平山病
    急性横断性脊髄炎
    脊髄空洞症
    HTLV-Ⅰ-associated myelopathy（HAM）
    亜急性脊髄連合変性症

    6．内科関連疾患
    肺性脳症
    低酸素脳症
    傍腫瘍性神経症候群
    糖尿病性昏睡（糖尿病性ケトアシドーシス）
    糖尿病性末梢神経障害
    髄膜癌腫症

    7．代謝性疾患
    ファブリー病
    Wilson病
    Wernicke脳症

    8．脱髄性および炎症性疾患
    多発性硬化症・視神経脊髄炎
    急性散在性脳脊髄炎
    神経ベーチェット病
    神経Sweet病

    9．末梢神経障害
    Guillain-Barré症候群
    Fisher症候群
    慢性炎症性脱髄性多発ニューロパチー（CIDP）
    多巣性運動ニューロパチー（MMN）
    M蛋白に伴うニューロパチー
    Charcot-Marie-Tooth病
    家族性アミロイドポリニューロパチー
    圧迫性ニューロパチー
    血管炎性ニューロパチー
    中毒性ニューロパチー
    特発性顔面神経麻痺（Bell麻痺）
    ICUAW（Intensive Care Unit-acquired weakness）
    神経痛性筋萎縮症（neuralgic amyotrophy）

    10．筋疾患
    多発性筋炎（PM）および皮膚筋炎（DM）を含む特発性炎症性筋疾患（IIM）
    重症筋無力症
    ランバート・イートン筋無力症候群
    周期性四肢麻痺
    筋ジストロフィー（デュシェンヌ型筋ジストロフィー）
    筋強直性ジストロフィー
    ミトコンドリア病
    筋痙攣

    11．機能性疾患
    神経痛
    慢性頭痛
    てんかん

    11．感染性疾患
    細菌性髄膜炎
    単純ヘルペス脳炎
    結核性髄膜炎
    HIV脳症
    リオン病

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1. 脳血管障害

P.5 掲載の参考文献
1) Adams HP, Jr., Bendixen BH, Kappelle LJ et al : Classification of subtype of acute ischemic stroke. definitions for use in a multicenter clinical trial. Toast. Trial of org 10172 in acute stroke treatment. Stroke 24 : 35-41, 1993
 
2) 日本脳卒中学会脳卒中医療向上・社会保険委員会静注 血栓溶解療法指針改訂部会 : 静注血栓溶解 (rt-pa) 療法 適正治療指針 第三版 2019年3月. 脳卒中 41 : 205-246, 2019
 
3) 日本脳卒中学会, 日本脳神経外科学会, 日本脳神経血管内治療学会 : 経皮経管的脳血栓回収用機器 適正使用指針 第4版. 脳卒中 42 : 281-313, 2020
Medical*Online
4) Grundy SM, Stone NJ, Bailey AL et al : 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol : a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation 139, 2019
 
5) Mach F, Baigent C, Catapano AL et al : 2019 ESC/EAS guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk. European Heart Journal 41 : 111-188, 2020
PubMed
P.10 掲載の参考文献
1) 日本脳卒中学会脳卒中ガイドライン委員会 編 : 脳卒中治療ガイドライン 2015 [追補2019対応]. 協和企画, 2019
 
2) 日本脳卒中学会 : 脳卒中治療ガイドライン 2021 (仮) https://kk-public-comments.jp/stroke2021/manuscript/index.html
 
3) Goyal M, Menon BK, van Zwam WH et al : Endovascular thrombectomy after large-vessel ischaemic stroke : a meta-analysis of individual patient data from five randomised trials. Lancet 387 : 1723-1731, 2016
PubMed
4) Saver JL, Goyal M, van der Lugt A et al : Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke : a meta-analysis. JAMA 316 : 1279-1288, 2016
PubMed
5) Nogueira RG, Jadhav AP, Haussen DC et al : Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 378 : 11-21, 2018
PubMed
6) Albers GW, Marks MP, Kemp S et al : Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med 378 : 708-718, 2018
PubMed
7) Fields JD, Khatri P, Nesbit GM et al : Meta-analysis of randomized intra-arterial thrombolytic trials for the treatment of acute stroke due to middle cerebral artery occlusion. J Neurointerv Surg 3 : 151-155, 2011
PubMed
8) Cerebral Embolism Task Force : Cardiogenic brain embolism. Arch Neurol 43 : 71-84, 1986
PubMed
9) Ad Hoc Committee of National Institute of Neurological Disorders and Stroke : Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 21 : 637-675, 1990
 
10) Adams HP Jr, Bendixen BH, Kappelle LJ et al : Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24 : 35-41, 1993
 
11) 高嶋修太郎 : 心原性脳塞栓症 (1) -病態と診断. "脳卒中ハンドブック 改訂第3版" 高嶋修太郎, 伊藤義彰 編. 診断と治療社, pp188-195, 2017
 
12) 日本脳卒中学会 脳卒中医療向上・社会保険委員会 静注血栓溶解療法指針改訂部会 : 静注血栓溶解 (rt-PA) 療法 適正治療指針 第三版, 2019
Medical*Online
13) 日本脳卒中学会, 日本脳神経外科学会, 日本脳神経血管内治療学会 : 経皮経管的脳血栓回収用機器 適正使用指針 第4版, 2020
Medical*Online
14) Edaravone Acute Infarction Group : Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 15 : 222-229, 2003
PubMed
15) Yamaguchi T, Awano H, Matsuda H, et al : Edaravone with and without.6 Mg/Kg Alteplase within 4.5 hours after ischemic stroke : a prospective cohort study. (PROTECT4.5) J Stroke Cerebrovasc Dis 26 : 756-765, 2017
PubMed
16) Aoki J, Kimura K, Morita N et al : YAMATO Study (Tissue-Type Plasminogen Activator and Edaravone Combination Therapy) Stroke 48 : 712-719, 2017
PubMed
17) Steffel J, Verhamme P, Potpara TS et al : The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39 : 1330-1393, 2018
PubMed
P.18 掲載の参考文献
1) 日本脳卒中学会脳卒中ガイドライン委員会 編 : 脳卒中治療ガイドライン 2015 [追補2019対応]. 協和企画, p iv, pp57-66, pp75-76, pp104-127, 2019
 
2) Fisher CM : The arterial lesions underlying lacunes. Acta Neuropathol 12 : 1-15, 1968
PubMed
3) Kato H, Izumiyama M, Izumiya K et al : Silent cerebral microbleeds on T2*-weighted MRI : Correlation with stroke subtype, stroke recurrence, and leukoaraiosis. Stroke 33 : 1536-1540, 2002
 
4) Koennecke HC : Cerebral microbleeds on MRI : prevalence, associations, and potential clinical implications. Neurology 66 : 165-171, 2006
PubMed
5) Ueno Y, Kimura K, Iguchi Y et al : Right-to-left shunt and lacunar stroke in patients without hypertension and diabetes. Stroke 68 : 528-531, 2007
PubMed
6) Wang Y, Zhao X, Liu L et al : Clopidgrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 369 : 11-19, 2013
PubMed
7) 奥田聡, 山口武典 : エダラボン臨床報告併合解析 (メタアナリシスの手法を用いて). 脳卒中 28 : 378-384, 2006
 
8) Uchiyama S, Shinohara Y, Katayama Y et al : Benefit of cilostazol in patients with high risk of bleeding : Subanalysis of Cilostazol Stroke Prevention Study 2. Cerebrovasc Dis 37 : 296-303, 2014
PubMed
P.23 掲載の参考文献
1) 日本脳卒中学会脳卒中ガイドライン委員会 編 : 脳卒中治療ガイドライン 2015 [追補2017対応]. II 脳梗塞・TIA, 2 TIA の急性期治療と再発予防. 協和企画, pp83-89, 2017
 
2) 日本脳卒中学会 : TIA定義について. 2019年10月12日
 
3) 峰松一夫 : TIA診療マニュアル. 厚生労働科学研究費補助金 一過性脳虚血発作 (TIA) の診断基準の再検討, ならびにわが国の医療環境に則した適切な診断・治療システムの確立に関する研究. 2012
 
4) Ueda K, Kiyohara Y, Hasuo Y et al : Transient cerebral ischemic attack in a Japanese community, Hisayama, Japan. Stroke 18 : 844-848, 1987
 
5) Johnston SC, Gress DR, Browner WS et al : Short-term prognosis after emergency department diagnosis of TIA. JAMA 284 : 2901-2906, 2000
PubMed
6) Lisabeth LD, Ireland JK, Risser JM et al : Stroke risk after transient ischemic attack in a population-based setting. Stroke 35 : 1842-1846, 2004
 
7) Wu CM, McLaughlin K, Lorenzetti DL et al : Early risk of stroke after transient ischemic attack : a systematic review and meta-analysis. Arch Intern Med 167 : 2417-2422, 2007
PubMed
8) Rothwell PM, Giles MF, Flossmann E et al : A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet 366 : 29-36, 2005
PubMed
9) Johnston SC, Rothwell PM, Nguyen-Huynh MN et al : Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 369 : 283-292, 2007
PubMed
10) Kiyohara T, Kamouchi M, Kumai Y et al : ABCD3 and ABCD3-I scores are superior to ABCD2 score in the prediction of short- and long-term risks of stroke after transient ischemic attack. Stroke 45 : 418-425, 2014
 
11) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 324 : 71-86, 2002
PubMed
12) Geeganage CM, Diener HC, Algra A et al : Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack : systematic review and meta-analysis of randomized controlled trials. Stroke 43 : 1058-1066, 2012
 
13) Collaborative overview of randomised trials of antiplatelet therapy-1 : Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 308 : 81-106, 1994
PubMed
14) Hart RG, Benavente O, McBride R et al : Antithrombotic therapy to prevent stroke in patients with atrial fibrillation : a meta-analysis. Ann Intern Med 131 : 492-501, 1999
PubMed
15) Yamaguchi T : Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative study Group. Stroke 31 : 817-821, 2000
 
16) Ntaios G, Papavasileiou V, Diener HC et al : Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack : a systematic review and meta-analysis of randomized controlled trials. Stroke 43 : 3298-3304, 2012
 
P.28 掲載の参考文献
1) 脳ドックのガイドライン2019改訂委員会 編 : 脳ドックのガイドライン 2019. 響文社, 2019
 
2) Bokura H, Kobayashi S, Yamaguchi S et al : Silent brain infarction and subcortical white matter lesions increase the risk of stroke and mortality : a prospective cohort study. J Stroke Cerebrovascular Diseases 15 : 57-63, 2006
 
3) Bokura H, Saika R, Yamaguchi T et al : Microbleeds are associated with subsequent hemorrhagic and ischemic stroke in healthy elderly individuals. Stroke 42 : 1867-1871, 2011
PubMed
4) Snowdon DA, Greiner LH, Mortimer JA et al : Brain Infarction and the Clinical Expression of Alzheimer Disease, The Nun Study. JAMA 277 : 813-817, 1997
PubMed
5) 細矢貴亮, 佐々木真理 編 : 研修医必携救急で役立つ頭部CT・MRI. 南江堂, 2006
 
P.32 掲載の参考文献
1) 高木誠 : 脳動脈解離 (Cerebral artery dissection) の診断と治療の手引き. "若年性脳卒中診療の手引き. 循環器病研究委託費12 指-2 若年世代の脳卒中の診断, 治療, 予防戦略に関する全国多施設共同研究" 主任研究者 峰松一夫. 国立循環器病センター内科脳血管部門, pp85-90, 2003
 
2) 松岡秀樹 : 脳動脈解離の現状 (2) 本邦の実態 (アンケート調査, 後ろ向き登録研究から). "脳動脈解離診療の手引き. 循環器病研究委託費18 公-5 (SCADS-Japan) 脳血管解離の病態と治療法の開発" 主任研究者 峰松一夫. 国立循環病センター内科脳血管部門, pp8-14, 2009
 
3) 高木誠 : 脳動脈解離. Clin Neurosci 38 : 635-637, 2020
 
4) 脳卒中治療ガイドライン委員会 編 : 脳卒中治療ガイドライン 2021. 協和企画, 2021 (in press)
 
5) The CADISS trial Investigators : Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS) : a randomised trial. Lancet Neurol 14 : 361-367, 2015
PubMed
6) Markus HS, Levy C, King A et al : Antiplatelet therapy vs anticoagulation therapy in cervical artery dissection. The Cervical Artery Dissection in Stroke Study (CADISS). randomized clinical trial final results. JAMA Neurol 76 : 657-664, 2009
 
7) Caprio FZ, Bernstein RA, Alberts MJ et al : Efficacy and safety of novel oral anticoagulants in patients with cervical artery dissections. Cerebrovasc Dis 38 : 247-253, 2014
PubMed
8) Powers WJ, Rabinstein AA, Ackerson T et al : Guidelines for the early management of patients with acute ischemic stroke : 2019 update to the 2018 guidelines for the early management of acute ischemic stroke. a guideline for health professionals from the American Heart Association/American Stroke Association. Stroke 50 : e344-418, 2019
 
9) Daou B, Hammer C, Mouchtouris N et al : Anticogaulation vs antiplatelet treatment in patients with carotid and vertebral artery dissection : a study of 370 patients and literature review. Neurosurgery 80 : 368-379, 2017
 
10) 高木誠 : 脳動脈解離. 臨床神経 45 : 846-848, 2005
 
P.38 掲載の参考文献
1) 日本脳卒中学会脳卒中ガイドライン委員会 編 : 脳卒中治療ガイドライン 2015 [追補2019]. 協和企画, 2019
 
2) Hemphill JC, 3rd, Greenberg SM, Anderson CS et al : Guidelines for the Management of Spontaneous Intracerebral Hemorrhage : A Guideline for Healthcare Professionals From the American Heart Association/American. Stroke AssociationStroke 46 : 2032-2060, 2015
PubMed
3) Mendelow AD, Gregson BA, Fernandes HM et al : Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH) : a randomised trial. Lancet 365 : 387-397, 2005
 
4) Hattori N, Katayama Y, Maya Y et al : Impact of stereotactic hematoma evacuation on activities of daily living during the chronic period following spontaneous putaminal hemorrhage : a randomized study. J Neurosurg 101 : 417-420, 2004
PubMed
P.44 掲載の参考文献
1) 日本脳卒中学会脳卒中ガイドライン委員会 編 : 脳卒中診療ガイドライン 2015 [追補2019対応]. 協和企画, 2019
 
2) 吉田裕毅, 塩川芳昭 : 脳動脈瘤破裂によるくも膜下出血の最新治療. CURRENT THERAPY 35 : 73-78, 2017
 
3) 九社前実香, 清水寛平, 青木友浩 : 脳動脈瘤に対するマクロファージを標的とした新規薬物治療法開発の可能性. The Mt. Fuji Workshop on CVD 37 : 37-41, 2019
 
4) van Gijn J, Kerr RS, Rinkel GJ : Subarachnoid haemorrhage. Lancet 369 : 306-318, 2007
PubMed
5) de Rooij NK, Linn FH, van der Plas JA et al : Incidence of subarachnoid haemorrhage : a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry 78 : 1365-1372, 2007
PubMed
6) Andreasen TH, Bartek J, Andresen M et al : Modifiable risk factors for aneurysmal subarachnoid hemorrhage. Stroke 44 : 3607-3612, 2013
PubMed
7) Okamoto K, Horisawa R, Kawamura T et al : Family history and risk of subarachnoid hemorrhage : a case-control study in Nagoya, Japan. Stroke 34 : 422-426, 2003
PubMed
8) Hunt WE, Kosnik EJ : Timing and perioperative care in intracranial aneurysm surgery. Clin Neurosurg 21 : 79-89, 1974
PubMed
9) Drake CG : Report of World Federation of Neurological Surgeons Committee on a Universal Subarachnoid Hemorrhage Grading Scale. J Neurosurg 68 : 985-986, 1988
 
10) Fisher CM, Kistler JP, Davis JM : Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 6 : 1-9, 1980
PubMed
11) 小宮山雅樹, 石黒友也, 中島英樹 : Fisher group 4の誤解. 脳卒中の外科 43 : 232-233, 2015
Medical*Online
12) 宮脇哲, 斉藤延人 : 【動脈・静脈の疾患 (下) -最新の診断・治療動向-】動脈・静脈の疾患 (臓器別) 脳血管疾患 くも膜下出血 病因と病態. 日本臨牀 75 (増刊 5 動脈・静脈の疾患 (下)) : 647-651, 2017
 
13) 片岡大治, 中川俊祐, 高橋淳 : くも膜下出血に対する初期治療の現状と問題点. 脳神経外科ジャーナル 28 : 542-551, 2019
 
14) 波出石弘 : 軽症くも膜下出血の診断-見逃しを防ぐために. Clinical Neuroscience 31 : 440-442, 2013
 
15) Takagi Y, Hadeishi H, Mineharu Y et al : Initially missed or delayed diagnosis of subarachnoid hemorrhage : a nationwide survey of contributing factors and outcomes in Japan. J Stroke Cerebrovasc Dis 27 : 871-877, 2018
PubMed
16) Kassell NF, Torner JC, Jane JA et al : The International Cooperative Study on the Timing of Aneurysm Surgery. Part 2 : Surgical results. J Neurosurg. 73 : 37-47, 1990
 
17) Winn HR, Richardson AE, Jane JA : The long-term prognosis in untreated cerebral aneurysms : I. The incidence of late hemorrhage in cerebral aneurysm : a 10-year evaluation of 364 patients. Ann Neurol 1 : 358-370, 1977
 
18) Tanno Y, Homma M, Oinuma M et al : Rebleeding from ruptured intracranial aneurysms in North Eastern Province of Japan. a cooperative study. J Neurol Sci 258 : 11-6, 2007
PubMed
19) Grosset DG, McDonald I, Cockburn M et al : Prediction of delayed neurological deficit after subarachnoid haemorrhage : a CT blood load and Doppler velocity approach. Neuroradiology 36 : 418-421, 1994
 
20) Crowley RW, Medel R, Dumont AS et al : Angiographic vasospasm is strongly correlated with cerebral infarction after subarachnoid hemorrhage. Stroke 42 : 919-923, 2011
PubMed
21) Tamatani S, Sasaki O, Takeuchi S et al : Detection of delayed cerebral vasospasm, after rupture of intracranial aneurysms, by magnetic resonance angiography. Neurosurgery 40 : 748-753 ; discussion 753-754, 1997
 
22) Kwon OY, Kim YJ, Cho CS et al : The utility and benefits of external lumbar CSF drainage after endovascular coiling on aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc 43 : 281-287, 2008
PubMed
23) Sethi H, Moore A, Dervin J et al : Hydrocephalus : comparison of clipping and embolization in aneurysm treatment. J Neurosurg 92 : 991-994, 2000
PubMed
P.53 掲載の参考文献
1) 鈴木二郎, 高久晃, 旭方祺 他 : 日本人に多発する脳底部異常血管網示す症候群の検討-第2報 脳血管写における追跡-. 脳神経 18 : 897-908, 1966
 
2) Suzuki J, Takaku A : Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 20 : 288-299, 1969
PubMed
3) Kudo T : Spontaneous occlusion of circle of Willis. Neurology 18 : 485-496, 1968
PubMed
4) 工藤達之 : ウイリス動脈輪閉塞症-その歴史と発展. "ウイリス動脈輪閉塞症" 工藤達之 監修, 半田肇 他・編. シュプリンガー・フェアラーク, pp1-6, 1993
 
5) 富永悌二, 鈴木則宏, 宮本享 他 : もやもや病 (ウイリス動脈輪閉塞症) 診断・治療ガイドライン (改訂版). 脳卒中の外科 46 : 1-24, 2018
 
6) Miyamoto S, Yoshimoto T, Hashimoto N et al : Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease : results of the Japan Adult Moyamoya Trial. Stroke 45 : 1415-1421, 2014
PubMed
7) Kuriyama S, Kusaka Y, Fujimura M et al : Prevalence and clinicoepidemiological features of moyamoya disease in Japan : findings from a nationwide epidemiological survey. Stroke 39 : 42-47, 2008
PubMed
8) 山口啓二, 野川茂, 福内靖男 : Willis動脈輪閉塞症 (もやもや病) の全国調査. 神経内科 54 : 319-327, 2001
 
9) Kamada F, Aoki Y, Narisawa A et al : A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet 56 : 34-40, 2011
 
10) Liu W, Morito D, Takashima S et al : Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One 6 : e22542, 2011
PubMed
11) Miyatake S, Miyake N, Touho H et al : Homozygous c.14576G > A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology 78 : 803-810, 2012
PubMed
12) Mineharu Y, Takagi Y, Takahashi JC et al : Rapid progression of unilateral moyamoya disease in a patient with a family history and an RNF213 risk variant. Cerebrovasc Dis 36 : 155-157, 2013
 
13) Miyawaki S, Imai H, Shimizu M et al : Genetic analysis of RNF213 c.14576G > A variant in nonatherosclerotic Quasi-Moyamoya disease. J Stroke Cerebrovasc Dis 24 : 1075-1079, 2015
PubMed
14) Baba T, Houkin K, Kuroda S : Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry 79 : 900-904, 2008
PubMed
15) Houkin K, Nakayama N, Kuroda S et al : Novel magnetic resonance angiography stage grading for moyamoya disease. Cerebrovasc Dis 20 : 347-54, 2005
PubMed
16) 日本脳卒中学会脳卒中医療向上・社会保険委員会rt-PA (アルテプラーゼ) 静注療法指針改定部会 : rt-PA (アルテプラーゼ) 静注療法適正治療指針 第二版. 脳卒中 34 : 443-480, 2012
 
17) 日本脳卒中学会脳卒中ガイドライン委員会 編 : 脳卒中治療ガイドライン 2015. 協和企画, 2015
 
18) Kuroda S, Hashimoto N, Yoshimoto T et al : Radiological findings, clinical course, and outcome in asymptomatic moyamoya disease : results of multicenter survey in Japan. Stroke 38 : 1430-1435, 2007
PubMed
P.58 掲載の参考文献
1) 日本脳卒中学会脳卒中ガイドライン委員会 編 : 脳静脈・静脈洞閉塞症. "脳卒中治療ガイドライン 2015" 協和企画, 2015
 
2) 豊口裕樹, 細矢貴亮 : 脳静脈洞血栓症の画像診断. 分子脳血管病 9 : 392-396, 2010
 
3) Saposnik G, Barinagarrementeria F, Brown RD Jr et al : Diagnosis and management of cerebral venous thrombosis : a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42 : 1158-1192, 2011
PubMed
4) Coutinho JM, Ferro JM, Canhao P et al : Unfractionated or low-molecular weight heparin for the treatment of cerebral venous thrombosis. Stroke 41 : 2575-2580, 2010
PubMed
5) Misra UK, Kalita J, Chandra S et al : Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis : a randomized controlled trial. Eur J Neurol 19 : 1030-1036, 2012
 
6) Hon SF, Li HL, Cheng PW : Use of direct thrombin inhibitor for treatment of cerebral venous thrombosis. J Stroke Cerebrovasc Dis. 21 : 915. e11-5, 2012
 
7) Mohammadian R, Sohrabi B, Mansourizadeh R et al : Treatment of progressive cerebral sinuses thrombosis with local thrombolysis. Interv neuroradiol 18 : 89-96, 2012
PubMed
8) Stam J, Majoie Charles B L M, van Delden OM et al : Endovascular thrombectomy and thrombolysis for severe cerebral sinus thrombosis : a prospective study. Stroke 39 : 1487-1490, 2008
PubMed
9) Dentali F, Squizzato A, Gianni M et al : Safety of thrombolysis in cerebral venous thrombosis : a systematic review of the literature (Provisional abstract). Thromb Haemost 104 : 1055-1062, 2010
 
10) Einhaupl K, Stam J, Bousser MG et al : EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol 17 : 1229-1235, 2010
PubMed
11) Kwan J, Gunter A : Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis. Cochrane Database of Systematic Reviews CD005501, 2006
 
12) Aguiar de Sousa D, Mestre T, Ferro JM et al : Cerebral venous thrombosis in Behcet's disease : a systematic review. J Neurol 258 : 719-727, 2011
PubMed
13) Saadoun D, Wechsler B, Resche-Rigon M et al : Cerebral venous thrombosis in Behcet's disease. Arthritis Rheum 61 : 518-526, 2009
PubMed
P.62 掲載の参考文献
1) Davous P : CADASIL : a review with proposed diagnostic criteria. Eur J Neurol 5 : 219-233, 1998
PubMed
2) Mizuta I, Watanabe-Hosomi A, Koizumi T et al : New diagnostic criteria for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy in Japan. J Neurol Sci 381 : 62-67, 2017
PubMed
3) Goldstein LB, Adams R, Alberts MJ et al : Primary prevention of ischemic stroke : a guideline from the American Heart Association/American Stroke Association Stroke Council : cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group ; Cardiovascular Nursing Council ; Clinical Cardiology Council ; Nutrition, Physical Activity, and Metabolism Council ; and the Quality of Care and Outcomes Research Interdisciplinary Working Group : the American Academy of Neurology affirms the value of this guideline. Stroke 37 : 1583-1633, 2006
 
4) Hara K, Shiga A, Fukutake T et al : Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. N Engl J Med 360 : 1729-1739, 2009
PubMed
5) Shindo A, Tabei KI, Taniguchi A et al : A nationwide survey and multicenter registry-based database of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy in Japan. Front Aging Neurosci 12 : 216, 2020
PubMed
6) Tomimoto H, Ohtani R, Wakita H et al : Small artery dementia in Japan : radiological differences between CADASIL, leukoaraiosis and Binswanger's disease. Dement Geriatr Cogn Disord 21 : 162-169, 2006
PubMed
7) Nozaki H, Sekine Y, Fukutake T et al : Characteristic features and progression of abnormalities on MRI for CARASIL. Neurology 85 : 459-463, 2015
PubMed
8) Mizuno T, Kondo M, Ishigami et al : Cognitive impairment and cerebral hypoperfusion in a CADASIL patient improved during administration of lomerizine. Clin Neuropharmacol 32 : 113-116, 2009
 
9) Watanabe-Hosomi A, Mizuta I, Koizumi T et al : Effect of lomerizine hydrochloride on preventing strokes in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Clin Neuropharmacol 43 : 146-150, 2020
PubMed
10) Dichgans M, Markus HS, Salloway S et al : Donepezil in patients with subcortical vascular cognitive impairment : a randomised double-blind trial in CADASIL. Lancet Neurol 7 : 310-318, 2008
PubMed
11) Saito S, Ozaki A, Takahashi M et al : Clustering of multifocal cerebral infarctions in CADASIL : a case report. J Neurol 258 : 325-327, 2011
PubMed
P.67 掲載の参考文献
1) Vaughan CJ, Delanty N : Hypertensive emergencies. Lancet 356 : 411-417, 2000
PubMed
2) Oppenheimer BS, Fishberg AM : Hypertensive encephalopathy. Arch Intern Med 41 : 264-278, 1928
 
3) Sundt TM Jr, Sharbrough FW, Piepgras DG et al : Correlation of cerebral blood flow and electroencephalographic changes during carotid endarterectomy : with results of surgery and hemodynamics of cerebral ischemia. Mayo Clin Proc 56 : 533-543, 1981
PubMed
4) Williams B, Mancia G, Spiering W et al : 2018 ESC/ESH Guidelines for the management of arterial hypertension : The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension : The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 36 : 1953-2041, 2018
 
5) Amraoui F, Van Der Hoeven NV, Van Valkengoed IG et al : Mortality and cardiovascular risk in patients with a history of malignant hypertension : a case-control study. J Clin Hypertens (Greenwich) 16 : 122-126, 2014
PubMed
6) Vlcek M, Bur A, Woisetschlager C et al : Association between hypertensive urgencies and subsequent cardiovascular events in patients with hypertension. J Hypertens 26 : 657-662, 2008
PubMed
7) van Mook WN, Rennenberg RJ, Schurink GW et al : Cerebral hyperperfusion syndrome. Lancet Neurol 4 : 877-888, 2005
PubMed
8) Rangel-Castilla L, Spetzler RF, Nakaji P : Normal perfusion pressure breakthrough theory : a reappraisal after 35 years. Neurosurg Rev 38 : 399-404 ; discussion 404-405, 2015
 
9) Strandgaard S : Autoregulation of cerebral blood flow in hypertensive patients. The modifying influence of prolonged antihypertensive treatment on the tolerance to acute, drug-induced hypotension. Circulation 53 : 720-727, 1976
 
10) Zhang R, Witkowski S, Fu Q et al : Cerebral hemodynamics after short- and long-term reduction in blood pressure in mild and moderate hypertension. Hypertension 49 : 1149-1155, 2007
 
11) Auer LM : The pathogenesis of hypertensive encephalopathy : experimental data and their clinical relevance with special reference to neurosurgical patients. Acta Neurochir Suppl (Wien) 27 : 1-111, 1978
PubMed
12) Kontos HA, Wei EP, Navari RM et al : Responses of cerebral arteries and arterioles to acute hypotension and hypertension. Am J Physiol 234 : H371-383, 1978
PubMed
13) MacKenzie ET, Strandgaard S, Graham DI et al : Effects of acutely induced hypertension in cats on pial arteriolar caliber, local cerebral blood flow, and the blood-brain barrier. Circ Res 39 : 33-41, 1976
PubMed
14) Astarita A, Covella M, Vallelonga F et al : Hypertensive emergencies and urgencies in emergency departments : a systematic review and meta-analysis. J Hypertens 38 : 1203-1210, 2020
PubMed
15) Peixoto AJ : Acute severe hypertension. N Engl J Med 381 : 1843-1852, 2019
PubMed
16) van den Born BH, Lip GYH, Brguljan-Hitij J et al : ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother 5 : 37-46, 2019
PubMed
17) Miller JB, Suchdev K, Jayaprakash N et al : New developments in hypertensive encephalopathy. Curr Hypertens Rep 20 : 13, 2018
PubMed
18) Williams B, Mancia G, Spiering W et al : 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology : ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 36 : 2284-2309, 2018
 
19) Immink RV, van den Born BJ, van Montfrans GA et al : Cerebral hemodynamics during treatment with sodium nitroprusside versus labetalol in malignant hypertension. Hypertension 52 : 236-240, 2008
PubMed
20) Peacock WF, Varon J, Baumann BM et al : CLUE : a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. Crit Care 15 : R157, 2011
PubMed
21) Liu-DeRyke X, Levy PD, Parker D Jr et al : A prospective evaluation of labetalol versus nicardipine for blood pressure management in patients with acute stroke. Neurocrit Care 19 : 41-47, 2013
 
22) Peacock WF 4th, Hilleman DE, Levy PD et al : A systematic review of nicardipine vs labetalol for the management of hypertensive crises. Am J Emerg Med 30 : 981-993, 2012
PubMed
23) Strandgaard S : Autoregulation of cerebral circulation in hypertension. Acta Neurol Scand Suppl 66 : 1-82, 1978
PubMed
24) Lavin P : Management of hypertension in patients with acute stroke. Arch Intern Med 146 : 66-68, 1986
PubMed
P.72 掲載の参考文献
1) 日本循環器学会, 他 : 血管炎症候群の診療ガイドライン (2017年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2017_isobe_h.pdf (2021年1月4日閲覧)
 
2) Kobayashi S, Yano T, Matsumoto Y et al : Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan : the first government-supported nationwide survey. Arthritis Rheum 49 : 594-598, 2003
PubMed
3) Hunder GG, Bloch DA, Michel BA et al : The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33 : 1122-1128, 1990
PubMed
4) Salvarani C, Cantini F, Boiardi L et al : Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347 : 261-271, 2002
PubMed
P.77 掲載の参考文献
1) Miyakis S, Lockshin MD, Atsumi T et al : International consensus statement on an update of the classification criteria for definite anti-phospholipid syndrome (APS). J Thromb Haemost 4 : 295-306, 2006
 
2) Tektonidou MG, Andreoli L, Limper M et al : EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78 : 1296-1304, 2019
PubMed
3) Ohnishi N, Fujieda Y, Hisada R et al : Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome. Rheumatology (Oxford) 58 : 969-974, 2019
PubMed

2. 認知症を主とする疾患

P.83 掲載の参考文献
1) Saunders AM, Hulette O, Welsh-Bohmer KA et al : Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet 348 : 90-93, 1996
PubMed
2) Homma A, Takeda M, Imai Y et al : Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. a 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 11 : 299-313, 2000
 
3) Wimo A, Winblad B, Engedal K et al : An economic evaluation of donepezil in mild to moderate Alzheimer's disease : results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 15 : 44-54, 2003
PubMed
4) 池田俊也, 池上直己 : 抗痴呆薬ドネペジルの経済評価. 医療と社会 10 : 27-38, 2000
 
5) Pike KE, Savage G, Villemagne VL et al : Beta-amyloid imaging and memory in non-demented individuals : evidence for preclinical Alzheimer's disease Brain 130 : 2837-2844, 2007
PubMed
P.90 掲載の参考文献
1) 日本神経学会 監 : 認知症疾患診療ガイドライン 2017. 医学書院, 2017
 
2) Fujishiro H, Iseki E, Nakamura S et al : Dementia with Lewy bodies : early diagnostic challenges. Psychogeriatrics 13 : 128-138, 2013
PubMed
3) Burn DJ, Rowan EN, Allan LM et al : Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 77 : 585-589, 2006
PubMed
4) Ohta K, Takahashi K, Gotoh J et al : Screening for impaired cognitive domains in a large Parkinson's disease population and its application to the diagnostic procedure for Parkinson's disease dementia. Dement Geriatr Cogn Dis Extra 4 : 147-159, 2014
 
P.95 掲載の参考文献
1) Snowden JS, Neary D, Mann DM : Fronto-temporal lobar degeneration : fronto-temporal dementia, progressive aphasia, semantic dementia. Churchill Livingstone, 1996
 
2) D Alton S, Lewis J : Therapeutic and diagnostic challenges for frontotemporal dementia. Front Aging Neurosci 6 : 204, 2014
PubMed
3) Swartz JR, Miller BL, Lesser IM et al : Frontotemporal dementia : treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 58 : 212-216, 1997
PubMed
P.101 掲載の参考文献
1) 認知症疾患診療ガイドライン作成委員会 編 : 認知症疾患診療ガイドライン 2017. 医学書院, 2017
 
2) Matsui Y, Tanizaki Y, Arima H et al : Incidence and survival of dementia in a general population of Japanese elderly : the Hisayama study. J Neurol Neurosurg Psychiatry 80 : 366-370, 2009
 
3) Roman GC, Tatemichi TK, Erkinjuntti T et al : Vascular dementia : diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43 : 250-260, 1993
PubMed
4) Gorelick PB, Scuteri A, Black SE et al : Vascular contributions to cognitive impairment and dementia : a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42 : 2672-2713, 2011
PubMed
P.107 掲載の参考文献
1) Adams RD, Fisher CM, Hakim S et al : Symptomatic occult hydrocephalus with "normal" cerebrospinal-fluid pressure. a treatable syndrome. N Engl J Med 273 : 117-126, 1965
PubMed
2) 日本正常圧水頭症研究会, 特発性正常圧水頭症診療ガイドライン作成委員会 : 特発性正常圧水頭症診療ガイドライン. メディカルレビュー社, 2004
 
3) 日本正常圧水頭症学会, 特発性正常圧水頭症診療ガイドライン作成に関する研究班 監 : 特発性正常圧水頭症診療ガイドライン (第3版). メディカルレビュー社, 2020
 

3. 錐体外路症状を主とする疾患

P.115 掲載の参考文献
1) 「パーキンソン病診療ガイドライン」作成委員会 編 : パーキンソン病診療ガイドライン 2018. 医学書院, 2018
 
2) Langston JW : The Parkinson's complex : parkinsonism is just the tip of the iceberg. Ann Neurol 59 : 591-596, 2006
 
3) Galbiati A, Verga L, Giora E et al : The risk of neurodegeneration in REM sleep behavior disorder : A systematic review and meta-analysis of longitudinal studies. Sleep Med Rev 43 : 37-46, 2019
PubMed
4) Postuma RB, Berg D, Stern M et al : MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 30 : 1591-1601, 2015
PubMed
5) Lehericy S, Vaillancourt DE, Seppi K et al : The role of high-field magnetic resonance imaging in parkinsonian disorders : pushing the boundaries forward. Mov Disord 32 : 510-525, 2017
PubMed
P.120 掲載の参考文献
1) Litvan I, Agid Y, Calne D et al : Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) : report of the NINDS-SPSP international workshop. Neurology 47 : 1-9, 1996
PubMed
2) Hoglinger GU, Respondek G, Stamelou M et al. (44 authors), for the Movement Disorder Society-endorsed PSP Study Group : Clinical diagnosis of progressive supranuclear palsy : the movement disorder society criteria. Mov Disord 32 : 853-864, 2017
 
3) Lang AE : Treatment of progressive supranuclear palsy and corticobasal degeneration. Mov Disord. 20 (Suppl 12) : s83-91, 2005
 
P.126 掲載の参考文献
1) Adam OR, Jankovic J : Symptomatic treatment of Huntington disease. Neurotherapeutics 5 : 181-197, 2008
 
2) Wild EJ, Tabrizi SJ : Huntington's disease phenocopy syndromes. Curr Opin Neurol 20 : 681-687, 2007
PubMed
3) Bonelli RM, Hodl AK, Hofmann P et al : Neuroprotection in Huntington's disease : a 2-year study on minocycline. Int Clin Psycho-pharmacol 19 : 337-342, 2004
 
4) Lalic NM, Maric J, Svetel M et al : Glucose homeostasis in Huntington disease. Arch Neurol 65 : 476-480, 2008
PubMed
5) Tabrizi Targeting Huntingtin expression in patients with Huntington's disease. N Engl J Med 380 : 2307-2316, 2019.
PubMed
P.132 掲載の参考文献
1) 日下博文 : 本態性振戦に有効であるとのエビデンスのある薬剤は何か. "EBM 神経疾患の治療 2007-2008" 岡本幸市, 棚橋紀夫, 水澤英洋 編, 中外医学社, pp261-269, 2007
 
2) 日本神経治療学会治療指針作成委員会 編 : 標準的治療 : 本態性振戦. 2011
 
3) 柴崎浩 : 神経診断学を学ぶ人のために. 医学書院, 2009
 
4) Ferreira JJ, Mestre TA, Lyons KE et al ; MDS Task Force on Tremor and the MDS Evidence Based Medicine Committee : MDS evidence-based review of treatments for essential tremor. Mov Disord 34 (7) : 950-958, 2019
PubMed
5) Zesiewicz TA, Elble RJ, Louis ED et al : Evidence-based guideline update : treatment of essential tremor : report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology 77 (19) : 1752-1755, 2011
 
6) Ito H, Yamamoto K, Fukutake S et al : Two-year Follow-up Results of Magnetic Resonance Imaging-guided Focused Ultrasound Unilateral Thalamotomy for Medication-refractory Essential Tremor. Intern Med 59 (20) : 2481-2483, 2020
PubMed
P.139 掲載の参考文献
1) 宇川義一 : ビデオでみる不随意運動の基礎. 臨床神経 52 : 827-831, 2012
 
2) Yanagisawa N : Functions and dysfunctions of the basal ganglia in humans. Proc Jpn Acad Ser B Phys Biol Sci 94 : 275-304, 2018
PubMed
3) Ugawa Y : Voluntary and involuntary movements : A proposal from a clinician. Neurosci Res 156 : 80-87, 2020
PubMed
4) Zutt R, van Egmond ME, Elting JW et al : A novel diagnostic approach to patients with myoclonus. Nat Rev Neurol 11 : 687-697, 2015
PubMed
5) Martinez-Ramirez D, Walker RH, Rodriguez-Violante M, Gatto EM, Rare Movement Disorders Study Group of International Parkinson's Disease : Review of Hereditary and Acquired Rare Choreas. Tremor Other Hyperkinet Mov (N Y) 10 : 1-24, 2020
 

4. 脊髄小脳変性症・多系統萎縮症

P.147 掲載の参考文献
1) 「脊髄小脳変性症・多系統萎縮症診療ガイドライン」作成委員会 編 : 脊髄小脳変性症・多系統萎縮症診療ガイドライン 2018. 南江堂, 2018
 
2) 佐々木秀直, 運動失調症の医療基盤に関する調査研究班MSA分科会 : わが国の指定難病の診断基準 (案) 現行基準の課題と展望. Clin Neurosci 37 : 1113-1116, 2019
 
3) Watanabe H, Saito Y, Terao S et al : Progression and prognosis in multiple system atrophy : an analysis of 230 Japanese patients. Brain 125 (Pt 5) : 1070-1083, 2002
 
4) Miyai I, Ito M, Hattori N et al : Cerebellar ataxia rehabilitation trial in degenerative cerebellar diseases. Neurorehabil Neural Repair 26 : 515-522, 2012
PubMed

5. 脊髄症状を主とする疾患

P.152 掲載の参考文献
1) Nakamura M, Ishii K, Watanabe K et al : Surgical treatment of intramedullary spinal cord tumors : prognosis and complications. Spinal Cord 46 : 282-286, 2008
PubMed
2) Nakamura M, Ishii K, Ishii K et al : Long-term surgical outcomes for myxopapillary ependymomas of the cauda equina. Spine 34 : E756-760, 2009
PubMed
3) Nakamura M, Tsuji O, Fujiyoshi K et al : Long-term surgical outcomes of spinal meningiomas. Spine 37 : E617-623, 2012
PubMed
4) Xia Y, Ishii K, Nakamura M et al : The validity of intraoperative angiography for the treatment of spinal arteriovenous fistula. J Spinal Disord Tech 20 : 442-448, 2007
PubMed
5) 石井賢, 千葉一裕, 戸山芳昭 : Digital時代の脳神経画像診断-脊髄・脊椎疾患を疑ったとき-. medicina 42 : 470-473, 2004
 
6) 石井賢, 中村雅也 : 胸椎部脊髄疾患の症候と外科治療. 脊椎脊髄ジャーナル 22, 2009
 
7) 石井賢, 中村雅也 : 最新整形外科学大系 脊椎・脊髄 脊髄髄外腫瘍 (戸山芳昭). 中山書店, pp377-392, 2007
 
8) 石井賢, 中村雅也, 戸山芳昭 : 高齢者の脊椎脊髄疾患-脊髄腫瘍の治療-. 脊椎脊髄ジャーナル 20 : 668-672, 2007
 
9) 石井賢, 中村雅也, 渡辺航太 他 : 脊髄海綿状血管腫の治療戦略-臨床経過と画像所見からみた外科的治療のタイミング-. 日本脊椎脊髄病学会雑誌, 2008
Medical*Online
10) 中村雅也 : 最新整形外科学大系 脊椎・脊髄 脊髄髄内腫瘍. 中山書店, pp370-376, 2007
 
11) 中村雅也, 戸山芳昭 : 脊髄腫瘍の画像診断と治療.日本脊椎脊髄病学会雑誌 16 : 472-486, 2005
Medical*Online
12) 名越慈人, 中村雅也, 松本守雄 : 脊椎脊髄疾患 : 脊髄疾患の診断. Orthopaedics 30 : 53-63, 2017
 
P.157 掲載の参考文献
1)月本裕国 : 頚椎後縦靭帯化骨により脊髄圧迫症候を呈した1剖検例. 日外宝函 29 : 1003-1007, 1960
 
2) 日本整形外科学会診療ガイドライン委員会, 脊柱靱帯骨化症診療ガイドライン策定委員会 編 : 脊柱靱帯骨化症診療ガイドライン 2019. 南江堂, 2019
 
3) Nakajima M, Takahashi A, Tsuji T et al : A genome-wide association study identifies susceptibility loci for ossification of the posterior longitudinal ligament of the spine. Nat Genet 46 : 1012-1016, 2014
PubMed
4) Nakajima M, Kou I, Ohashi H : Identification and functional characterization of RSPO2 as a susceptibility gene for ossification of the posterior longitudinal ligament of the spine. Am J Hum Genet 99 : 202-207, 2016
PubMed
5) Tsuyama N : Ossification of the posterior longitudinal ligament of the spine. Clin Orthop 184 : 71-84, 1984
PubMed
6) 三橋孝之, 斉藤裕一, 近藤総一 他 : 頚椎後縦靭帯骨化の単純X線像における形態と骨化進展, とくに分節型・混合型にみられる2椎体に及ばない小骨化について. 整形外科 45 : 19-24, 1994
 
7) 高石官成, 松本守雄, 藤村祥一 : 頸椎後縦靱帯骨化症に対する片開き式脊柱管拡大術の長期成績. 厚生省特定疾患研究9年度研究報告書 骨・関節系疾患調査研究班, pp103-104, 1998
 
8) 岩崎幹季, 宮内晃, 奥田真也 他 : 頚椎後縦靭帯骨化症, 治療に関するシステマティックレビュー. 脊椎脊髄 19 : 133-142, 2006
 
9) Fujiyoshi T, Yamazaki M, Kawabe J et al : A new concept for making decisions regarding the surgical approach for cervical ossification of the posterior longitudinal ligament : the K-line. Spine (Phila Pa 1976) 33 : E990-E993, 2008
 
10) Takeuchi K, Yokoyama T, Numasawa T et al : K-line (-) in the neck-flexed position in patients with ossification of the posterior longitudinal ligament is a risk factor for poor clinical outcome after cervical laminoplasty. Spine (Phila Pa 1976) 41 : 1891-1895, 2016
PubMed
11) Koda M, Mochizuki M, Konishi H et al : Comparison of clinical outcomes between laminoplasty, posterior decompression with instrumented fusion, and anterior decompression with fusion for K-line (-) cervical ossification of the posterior longitudinal ligament. Eur Spine J 25 : 2294-2301, 2016
 
12) Matsunaga S, Sakou T, Hayashi K et al : Trauma-induced myelopathy in patients with the ossification of the posterior longitudinal ligament. J Neurosurg 97 (2 Suppl) : 172-175, 2002
 
13) 中村雅也・藤村祥一, 松本守雄 他 : 頚椎後縦靭帯骨化症の手術治療成績と外傷の関連について. 臨床整形外科 31 : 1339-1342, 1996
 
P.164 掲載の参考文献
1) Brooks BR, Miller RG, Swash M et al : El Escorial revisited : revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 1 : 293-299, 2000
 
2) de Carvalho M, Dengler R, Eisen A et al : Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 119 : 497-503, 2008
PubMed
3) Geevasinga N, Loy CT, Menon P et al : Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis : a systematic review using individual patient data. Clin Neurophysiol. 127 : 2684-2691, 2016
PubMed
4) Shefner JM, Al-Chalabi A, Baker MR : A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 131 : 1975-1978, 2020
PubMed
5) ALS治療ガイドライン作成小委員会 : ALS治療ガイドライン 2002. 臨床神経 42 : 676-719, 2002
 
6) 「筋萎縮性側索硬化症診療ガイドライン」作成委員会 編 : 筋萎縮性側索硬化症診療ガイドライン 2013, 南江堂, 2013
 
P.168 掲載の参考文献
1) 田中章景, 祖父江元 : 球脊髄性筋萎縮症 (Kennedy-Alter-Sung 病). 神経症候群 II, 領域別症候群シリーズ 27 (日本臨牀別冊). 日本臨牀社, pp375-378, 1999
 
2) 勝野雅央, 足立弘明, 坂野晴彦 他 : 医学と医療の最前線 球脊髄性筋萎縮症の治療法開発. 日本内科学雑誌 93 : 1466-1472, 2004
 
3) Suzuki K, Katsuno M, Banno H et al : CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA. Brain 131 : 229-239, 2008
PubMed
4) Atsuta N, Watanabe H, Ito M et al : Natural history of spinal and bulbar muscular atrophy (SBMA) : a study of 223 Japanese patients. Brain 29 (Pt 6) : 1446-1455, 2006
 
5) Hijikata Y, Hashizume A, Yamada S et al : Biomarker-based analysis of preclinical progression in spinal and bulbar muscular atrophy. Neurology 90 : e1501-e1509, 2018
PubMed
6) Araki A, Katsuno M, Suzuki K et al : Brugada syndrome in spinal and bulbar muscular atrophy. Neurology 82 : 1813-1821, 2014
PubMed
7) Katsuno M, Adachi H, Kume A et al : Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35 : 843-854, 2002
 
8) Katsuno M, Adachi H, Doyu M et al : Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 9 : 768-773, 2003
 
9) Hashizume A, Katsuno M, Suzuki K et al : Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy : natural history-controlled study. J Neurol Neurosurg Psychiatry 88 : 1026-1032, 2017
PubMed
P.173 掲載の参考文献
1) Mohr JP, Benavente S, Barnett HJM : Spinal cord ischemia. "Stroke : pathophysiology, diagnosis, and management" ed. Mohr JP et al. Churchill Livingstone, pp423-436, 2004
 
2) Nasr DM, Rabinstein A : Spinal cord infarcts : risk factors, management, and prognosis. Curr Treat Options Neurol 19 : 28, 2017
 
3) Weidauer S, Nichtweiss M, Hattingen E et al : Spinal cord ischemia : aetiology, clinical syndromes and imaging features. Neuroradiology 57 : 241-257, 2015
PubMed
4) Yuh WT, Marsh EE 3rd, Wang AK et al : MR imaging of spinal cord and vertebral body infarction. Am J Neuroradiol 13 : 145-154, 1992
PubMed
5) Fugate JE, Lanzino G, Rabinstein AAR : Clinical presentation and prognostic factors of spinal dural arteriovenous fistulas : an overview. Neurosurg Focus 32 : E17, 2012
 
6) Lenck S, Nicholson P, Tymianski R et al : Spinal and paraspinal arteriovenous lesions. Stroke 50 : 2259-2269, 2019
PubMed
7) Zozulya YP, Slin'ko EI, Al-Qashqish II : Spinal arteriovenous malformations : new classification and surgical treatment. Neurosurg Focus 20 : E7, 2006
 
P.176 掲載の参考文献
1) 平山惠造, 豊倉康夫, 椿忠雄 : 筋萎縮症の一新特異型の存在について-若年に発病し一側前腕より末梢に限局する進行の遅い特殊な筋萎縮症-. 精神経誌 61 : 2190-2197, 1959
 
2) 平山惠造, 朝長正徳, 北野邦孝 他 : 若年性一側上肢筋萎縮症の初剖検例. 神経内科 22 : 85-88, 1985
 
3) 向井栄一郎, 祖父江逸郎, 武藤多津郎 他 : 若年性上肢遠位部髄節性筋萎縮症のレ線学的異常所見. 臨床神経 25 : 620-626, 1985
 
4) 向井栄一郎, 松尾敏和, 武藤多津郎 他 : 若年性上肢遠位部髄節性筋萎縮症のMRI. 臨床神経 27 : 99-107, 1987
 
5) 得丸幸夫, 平山惠造 : 若年性一側上肢筋萎縮症 (平山病) の頚椎カラー療法-38例での治療成績-. 臨床神経 41 : 173-178, 2001
 
P.182 掲載の参考文献
1) 日本神経学会 監 : 急性横断性脊髄炎. "多発性硬化症・視神経脊髄炎診療ガイドライン 2017" 医学書院, pp13-15, 2017
 
2) Lennon VA, Kryzer TJ, Pittock SJ et al : IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202 : 473-477, 2005
 
3) Waters P, Pittock SJ, Bennet JL et al : Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol 5 : 290-303, 2014
 
4) Watanabe S, Nakashima I, Misu T et al : Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 13 : 128-132, 2007
PubMed
5) Watanabe S, Misu T, Miyazawa I et al : Low-dose corticosteroids reduce relapses in neuromyelitis optica : a retrospective analysis. Mult Scler 13 : 968-974, 2007
PubMed
P.185 掲載の参考文献
1) 阿部俊昭 : 脊髄空洞症. "脳神経外科学大系 11巻 脊椎・脊髄疾患・末梢神経・自律神経疾患" 山浦晶, 橋本信夫 編. 中山書店, pp314-319, 2005
 
2) 阿部俊昭 他 : 脊髄空洞症の症状推移と神経症状発現機序についての考察. 臨神経 32 : 979-983, 1992
 
P.192 掲載の参考文献
1) 厚生労働省「HAMならびにHTLV-1陽性難治性疾患に関する国際的な総意形成を踏まえた診療ガイドラインの作成」研究班. 「HTLV-1関連脊髄症 (HAM) 診療ガイドライン 2019」作成委員会 編 : HTLV-1関連脊髄症 (HAM) 診療ガイドライン 2019. 南江堂, 2019
 
2) Bangham CR, Araujo A, Yamano Y et al : HTLV-I-associated myelopathy/tropical spastic paraparesis. Nat Rev Dis Primers 1 : 15012, 2015
PubMed
3) Sato T, Yagishita N, Tamaki K et al : Proposal of classification criteria for HTLV-1-associated myelopathy/tropical spastic paraparesis disease activity. Front Microbiol, 9 : 1651, 2018
PubMed
4) Yamakawa N, Yagishita N, Matsuo T et al : Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis. Orphanet J Rare Dis 15 : 175, 2020
PubMed
5) Nagasaka M, Yamagishi M, Yagishita N et al : Mortality and risk of progression to adult T cell leukemia/lymphoma in HTLV-1-associated myelopathy/tropical spastic paraparesis. Proc Natl Acad Sci USA 117 : 11685-11691, 2020
PubMed
P.195 掲載の参考文献
1) 永石彰子, 黒田康夫 : ビタミンB12の吸収・代謝・利用と神経障害. 神経内科 61 : 319-323, 2004
 
2) 佐々木良元, 葛原茂樹 : ビタミンB12欠乏性神経障害. "別冊日本臨牀 領域別症候群シリーズ No.29 神経症候群 IV" 日本臨牀社, pp95-97, 2000
 
3) 田口朋広, 中野今治 : ビタミンB12欠乏と亜急性脊髄連合変性症. 神経内科 61 : 329-333, 2004
 

6. 内科関連疾患

P.203 掲載の参考文献
1) 日本呼吸器学会NPPVガイドライン作成委員会 編 : NPPV (非侵襲的陽圧換気療法) ガイドライン (改訂第2版). 南江堂, 2015
 
2) 日本呼吸ケア・リハビリテーション学会酸素療法マニュアル作成委員会, 日本呼吸器学会肺生理専門委員会 編 : 酸素療法マニュアル (酸素療法ガイドライン 改訂版). 2017
 
3) 鈴木昌 : 救急患者に対する系統的アプローチ. "内科救急診療指針 2016" 日本内科学会 編. 日本内科学会, pp2-10, 2016
 
4) 西川正憲 : 呼吸困難の成因と分類. 内科 123 : 5-8, 2019
 
5) 西川正憲 : 救急患者の初期対応は何が大切か? 呼吸器ジャーナル 66 : 6-14, 2018
 
P.209 掲載の参考文献
1) Wijdicks EFM, Hijdra A, Young GB et al : Practice parameter : prediction of outcome in comatose survivors after cardiopulmonary resuscitation (an evidenced-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neuro-logy 67 : 203-210, 2006
 
2) Marion Moseby-Knappe M, Westhall E, Backman S et al : Performance of a guideline-recommended algorithm for prognostication of poor neurological outcome after cardiac arrest. Intensive Care Med 46 : 1852-1862, 2020
PubMed
3) 中村敏弘, 畝本恭子, 横田裕行 : 蘇生後脳症に対する脳低体温療法の現況. 救急医学 23 : 1856-1860, 1999
 
4) ECC Committee, Subcommittees and Task Forces of the American Heart Association : 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 112 (suppl 24) : IV1-203, 2005
 
5) Correia AO, Feitosa PWG, Moreira JLS et al : Neurological manifestations of COVID-19 and other coronaviruses : a systematic review. Neurol Psychiatry Brain Res 37 : 27-32, 2020
PubMed
P.221 掲載の参考文献
1) Graus F, Delattre JY, Antoine JC et al : Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75 : 1135-1140, 2004
PubMed
2) Vedeler CA, Antoine JC, Giometto B et al : Paraneoplastic Neurological Syndrome Euronetwork. Management of paraneoplastic neurological syndromes : report of an EFNS Task Force. Eur J Neurol 13 : 682-690, 2006
PubMed
3) Titulaer MJ, Soffietti R, Dalmau J et al : Screening for tumours in paraneoplastic syndromes : report of an EFNS task force. Eur J Neurol 18 : 19-e3, 2011
 
4) Darnell RB : Onconeural antigens and the paraneoplastic neurologic disorders : at the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci USA 93 : 4529-4536, 1996
PubMed
5) Darnell RB, Posner JB : Paraneoplastic syndromes involving the nervous system. N Engl J Med 349 : 1543-1554, 2003.
PubMed
6) 犬塚貴 : 自己免疫性脳炎・脳症 悪性腫瘍に伴う自己免疫性脳炎. BRAIN and NERVE 68 : 1049-1055, 2016
 
7) Giometto B, Grisold W, Vitaliani R et al : Paraneoplastic neurologic syndrome in the PNS Euronetwork database : a European study from 20 centers. Arch Neurol 67 : 330-335, 2010
PubMed
8) Ances BM, Vitaliani R, Taylor RA et al : Treatment-responsive limbic encephalitis identified by neuropil antibodies : MRI and PET correlates. Brain 128 : 1764-1777, 2005
PubMed
9) Vincent A, Buckley C, Schott JM et al : Potassium channel antibody-associated encephalopathy : a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127 : 701-712, 2004
PubMed
10) Thieben MJ, Lennon VA, Boeve BF et al : Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 62 : 1177-1182, 2004
PubMed
11) 渡邊修, 有村公良 : 傍腫瘍性神経症候群 : 診断と治療の進歩 最近の話題 抗チャネル抗体. 日本内科学会雑誌 97 : 1838-1843, 2008
 
12) Graus F, Titulaer MJ, Balu R et al : A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15 : 391-404, 2016
PubMed
13) 田中恵子 : 傍腫瘍性小脳変性症. 日本臨牀 別冊 神経症候群 (第2版) II, 日本臨牀社, pp747-750, 2014
 
14) Koike H, Sobue G : Paraneoplastic neuropathy. Handb Clin Neurol 115 : 713-726, 2013
PubMed
15) Koike H, Watanabe H, Sobue G : The spectrum of immune-mediated autonomic neuropathies : insights from the clinicopathological features. J Neurol Neurosurg Psychiatry 84 : 98-106, 2013
PubMed
16) 桑原聡 : 最新のニューロパチー診療 腫瘍に伴うニューロパチー (傍腫瘍性ニューロパチー). 日本内科学会雑誌 108 : 1562-1565, 2019
 
17) Lorish TR, Thorsteinsson G, Howard FM Jr : Stiff-man syndrome updated. Mayo Clin Proc 64 : 629-636, 1989
PubMed
18) 渡邊修 : Issacs症候群の診断, 疫学および病態解明に関する研究. 厚生労働科学研究費補助金 難治性疾患等克服研究事業 免疫性神経疾患に関する調査研究 平成24年度総括・分担研究報告書. pp78-79, 2013
 
19) Irani SR, Alexander S, Waters P et al : Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 133 : 2734-2748, 2010
 
20) Irani SR, Pettingill P, Kleopa KA et al : Morvan syndrome : clinical and serological observations in 29 cases. Ann Neurol 72 : 241-255, 2012
PubMed
21) Graus F, Saiz A, Dalmau J : Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 257 : 509-517, 2010
PubMed
22) Didelot A, Honnorat J : Update on paraneoplastic neurological syndromes. Curr Opin Oncol 21 : 566-572, 2009
PubMed
23) Dalmau J : NMDA receptor encephalitis and other antibody-mediated disorders of the synapse : The 2016 Cotzias Lecture. Neurology 87 : 2471-2482, 2016
PubMed
24) Graus F, Dalmau J : Paraneoplastic neurological syndromes. Curr Opin Neurol 25 : 795-801, 2012
PubMed
25) Dalmau J, Rosenfeld MR : Paraneoplastic syndromes of the CNS. Lancet Neurol 7 : 327-340, 2008
PubMed
26) 河内泉 : Antibody Update 2018 傍腫瘍性神経症候群と自己抗体. BRAIN and NERVE 70 : 329-339, 2018
 
27) Graus F, Keime-Guibert F, Rene R et al : Anti-Hu-associated paraneoplastic encephalomyelitis : analysis of 200 patients. Brain 124 : 1138-1148, 2001
PubMed
28) Dalmau J, Graus F, Villarejo A et al : Clinical analysis of anti-Ma2-associated encephalitis. Brain 127 : 1831-1844, 2004
PubMed
29) Honnorat J, Cartalat-Carel S, Ricard D et al : Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 80 : 412-416, 2009
PubMed
30) De Camilli P, Thomas A, Cofiell R et al : The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med 178 : 2219-2223, 1993
PubMed
31) Honnorat J, Antoine JC : Paraneoplastic neurological syndromes. Orphanet J Rare Dis 2 : 22, 2007
PubMed
32) Dalmau J, Lancaster E, Martinez-Hernandez E et al : Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 10 : 63-74, 2011
PubMed
P.228 掲載の参考文献
1) 日本糖尿病学会 編 : 20. 糖尿病における急性代謝失調・シックデイ (感染症を含む). "糖尿病診療ガイドライン 2019" 南江堂, pp329-345, 2019
 
2) Kitabchi AE, Umpierrez GE, Miles JM et al : Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32 : 1335-1343, 2009
PubMed
3) 劇症1型糖尿病調査研究委員会 : 劇症1型糖尿病調査研究委員会報告-疫学調査の解析と診断基準の策定-. 糖尿病 48 (Suppl 1) : A1-A13, 2005
 
4) Peters AL, Buschur EO, Buse JB et al : Euglycemic diabetic ketoacidosis : a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 : 1687-1693, 2015
PubMed
P.232 掲載の参考文献
1) 日本糖尿病学会 編著 : 糖尿病ガイドライン 2019. 南江堂, pp169-180, 2019
 
2) 糖尿病性末梢神経障害を考える会 : 糖尿病性多発神経障害の簡易診断基準の改定について. 末梢神経 14 (2) : 225-227, 2003
 
3) Pop-Busui R, Boulton AJ, Feldman EL et al : Diabetic neuropathy : a position statement by the American Diabetes Association. Diabetes Care 40 : 136-154, 2017
PubMed
P.237 掲載の参考文献
1) Le Rhun E, Weller M, Brandsma D et al : EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol 28 (Suppl. 4) : iv84-iv99, 2017
 
2) 中洲庸子 : 固形癌からの髄膜癌腫症 : 分子標的治療時代の臨床. Neuro-Oncologyの進歩 25 : 10-22, 2018
 
3) 日本脳腫瘍学会 : 脳腫瘍診療ガイドライン 2019 https://www.jsn-o.com/guideline3/index1.html (2021年2月1日閲覧)
 
4) 日本肺癌学会 : 肺癌診療ガイドライン 2020年版 https://www.haigan.gr.jp/guideline/2020/1/2/200102080100.html (2021年2月1日閲覧)
 
5) 日本乳癌学会 : 乳癌診療ガイドライン (2021年2月1日閲覧) http://jbcs.gr.jp/guidline/2018/index/yakubutu/y2-fq-11/
 
6) National Comprehensive Cancer Network (2021年2月1日閲覧) https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
 

7. 代謝性疾患

P.243 掲載の参考文献
1. Schiffman R et al. JAMA 285 : 2743, 2001
 
1. Banikazemi M et al. Ann Int Med 146 : 77, 2007
PubMed
2. Thurnberg BL et al. Kidney Int 62 : 1933, 2002
 
2. Eng CM et al. Am J Hum Gent 68 : 711, 2001
 
3. Beck M et al. Eur J Clin Invest 34 : 838, 2004
PubMed
4. Weidemann F et al. Circulation 119 : 524, 2009
PubMed
P.245 掲載の参考文献
1. Banikazemi M et al. Ann Int Med 146 : 77, 2007
PubMed
2. Thurnberg BL et al. Kidney Int 62 : 1933, 2002
 
P.246 掲載の参考文献
1) 衞藤義勝 : ファブリー病診療ガイドライン 2019 (厚生労働省難治性疾患政策事業) ライソゾーム病研究班 (衛藤班)
 
2) 衞藤義勝 編 : ファブリー病 Up Date. 診断と治療社, 2009
 
P.250 掲載の参考文献
1) 玉井浩 : Wilson病. 別冊・医学のあゆみ 消化器疾患 II. 胆・肝・膵. 医歯薬出版. pp611-613, 2006
 
2) 青木継稔 : Wilson病研究の進展-わが国におけるWilson病患者の自然歴の解明と分子病態解析に関する研究-. 日本先天代謝異常学会雑誌 20 : 18-26, 2004
 
3) 藤井秀樹 : 発症前Wilson病のセルロプラスミンおよび銅代謝異常に関する研究-診断基準作成の試み-. Biomed Res Trace Elements 8 : 75-83, 1997
 
4) 青木継稔, 原まどか, 鈴木真理子 他 : Wilson病の全国追跡調査成績. 小児内科 23 : 1893-1898, 1991
 
5) 日本小児栄養消化器肝臓学会 編 : Wilson病診療ガイドライン 2015. "小児の栄養消化器肝臓病診療ガイドライン・指針" 診断と治療社, 2015
 
P.256 掲載の参考文献
1) Galvin R, Brathen G, Ivashynka A et al : EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol 17 : 1408-1418, 2010
PubMed
2) Wernicke, C : Die akute hamorrhagische polioencephalitis superior. In : "Lehrbuch der Gehirnkrankheiten fur Arzte und Studirende" ; Bd. 2, Theodor Fischer, Kassel, pp229-242, 1881
 
3) 小阪憲司, 池田研二 : II. 歴史的事項. ウェルニッケ・コルサコフ脳症. 星和書店, pp2-22, 1984
 
4) Caine D, Halliday GM, Kril JJ et al : Operational criteria for the classification of chronic alcoholics : identification of Wernicke's encephalopathy. J Neurol Neurosurg Psychiatry 62 : 51-60, 1997
PubMed

8. 脱髄性および炎症性疾患

P.263 掲載の参考文献
1) 「多発性硬化症・視神経脊髄炎診療ガイドライン」作成委員会 編 : 多発性硬化症・視神経脊髄炎診療ガイドライン 2017. 医学書院, 2017
 
2) Nakashima I : Anti-myelin oligodendrocyte glycoprotein antibody in demyelinating diseases. Clinical and Experimental Neuroimmunology 6 : 59-63, 2015
 
3) Thompson AJ, Banwell BL, Barkhof F et al : Diagnosis of multiple sclerosis : 2017 revisions of the McDonald criteria. Lancet Neurol 17 : 162-173, 2018
PubMed
4) Wingerchuk DM, Banwell B, Bennett JL et al : International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85 : 177-189, 2015
PubMed
P.267 掲載の参考文献
1) Krupp LB, Banwell B, Tenembaum S : Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Review Neurology 68 (16 Suppl 2) : S7-S12, 2007
 
2) Krupp LB, Tardieu M, Amato MP et al : International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders : revisions to the 2007 definitions. Mult Scler 19 : 1261-1267, 2013
 
3) 「多発性硬化症・視神経脊髄炎診療ガイドライン」作成委員会 編 : 多発性硬化症・視神経脊髄炎診療ガイドライン 2017. 医学書院, pp10-12, pp111-113, 2017
 
4) 高田和男, 楠進 : 急性散在性脳脊髄炎. CLINICAL NEUROSCIENCE 22 : 824-825, 2004
 
5) 磯田治夫, 中根正人, 河村泰孝 : 脱髄疾患 急性散在性脳脊髄炎と感染関連脱髄疾患. 臨床画像 21 : 326-334, 2005
 
6) 葛原茂樹 : 成人の急性ウイルス性脳脊髄炎と急性散在性脳脊髄炎. Neuroinfection 12 : 3-10, 2007
 
7) Pohl D, Alper G, Van Haren K et al : Acute disseminated encephalomyelitis : Updates on an inflammatory CNS syndrome. Neurology 87 (9 Suppl 2) : S38-S45, 2016
 
P.271 掲載の参考文献
1) 日本ベーチェット病学会, 厚生労働科学研究費補助金 (難治性疾患政策研究事業) ベーチェット病に関する調査研究班 : ベーチェット病診療ガイドライン 2020
 
2) Kirino Y, Bertsias G, Ishigatsubo Y et al : Genome-wide association analysis identifies new susceptibility loci for Behcet's disease and epistasis between HLA-B* 51 and ERAP1. Nat Genet 45 : 202-207, 2013
PubMed
3) Addimanda O, Pipitone N, Pazzola G et al : Tocilizumab for severe refractory neuro-Behcet : three cases IL-6 blockade in neuro-Behcet. Semin Arthritis Rheum 44 : 472-475, 2015
PubMed
P.275 掲載の参考文献
1) Nofal A, Abdelmaksoud A, Amer H et al : Sweet's syndrome : diagnostic criteria revisited. J Deutsch Dermatol Ges 15 : 1081-1088, 2017
 
2) Hisanaga K, Hosokawa M, Sato N et al : "Neuro-Sweet disease" Benign recurrent encephalitis with neutrophilic dermatosis. Arch Neurol 56 : 1010-1013, 1999
PubMed
3) Hisanaga K, Iwasaki Y, Itoyama Y et al : Neuro-Sweet disease : Clinical manifestations and criteria for diagnosis. Neurology 64 : 1756-1761, 2005
PubMed
4) 久永欣哉 : ベーチェット病およびその類縁疾患スウィート病における神経障害の病因・診断・治療. 臨床神経 59 : 1-12, 2019
 
5) Mizoguchi M, Matsuki K, Mochizuki M et al : Human leukocyte antigen in Sweet's syndrome and its relationship to Behcet's disease. Arch Dermatol 124 : 1069-1073, 1988
PubMed
6) Fukae J et al : Successful treatment of relapsing neuro-Sweet's disease with corticosteroid and dapson combination therapy. Clin Neurol Neurosurg 109 : 910-913, 2007
PubMed
7) Hisanaga K : Neuro-neutrophilic disease : Neuro-Behcet disease and neuro-Sweet disease. Intern Med 46 : 153-154, 2007
PubMed

9. 末梢神経障害

P.280 掲載の参考文献
1) 「ギラン・バレー症候群, フィッシャー症候群診療ガイドライン」作成委員会 編 : ギラン・バレー症候群, フィッシャー症候群診療ガイドライン 2013. 南江堂, 2013
 
2) 桑原基, 楠進 : 免疫性ニューロパチー. 日本内科学会雑誌 108 : 1524-1529, 2019
 
3) Takada K, Shimizu J, Kusunoki S : Apoptosis of primary sensory neurons in GD1b-induced sensory ataxic neuropathy. Exp Neurol 209 : 279-283, 2008
PubMed
4) 楠進 : リピドラフトの自己免疫からみた末梢神経障害Guillain-Barre症候群をモデルとして. Medical Science Digest 34 : 18-21, 2008
 
5) 濱口勝彦, 野村恭一 : ギラン・バレー症候群における献血ベニロン-Iの使用成績調査中間報告. 診療と新薬 43 : 1175-1190, 2006
 
6) Walgaard C, Lingsma HF, Ruts L et al : Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology 76 : 968-975, 2011
PubMed
7) 山岸裕子, 楠進 : ギラン・バレー症候群の予後と予後予測因子. 臨床神経 60 : 247-252, 2020
 
P.284 掲載の参考文献
1) Fisher M : An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 255 : 57, 1956
PubMed
2) Chiba A, Kusunoki S, Obata H et al : Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome : clinical and immunohistochemical studies. Neurology 43 : 1911, 1993
PubMed
3) Kaida K, Kusunoki S, Kanzaki M et al : Anti-GQ1b antibody as a factor predictive of mechanical ventilation in Guillain-Barre syndrome. Neurology 62 : 821, 2004
PubMed
P.295 掲載の参考文献
1) Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 41 : 617-618, 1991
 
2) Joint Task force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : report of a joint force of the Peripheral Nerve Society-First revision. J Peripher Nerv syst 15 : 1-9, 2010
 
3) 「慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン」作成委員会 編 : 慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン 2013. 南江堂, 2013
 
4) Bunschoten C, Jacobs BC, Van den Bergh PYK et al : Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol 18 : 784-794, 2019
PubMed
5) Kieseir BC, Mathey EK, Sommer C et al : Immune-mediated neuropathies. Nat Rev Dis Primers 4 : 31, 2018
 
P.299 掲載の参考文献
1) Joint Task Force of the EFNS and the PNS : European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and Peripheral Nerve Society-first revision. J Peripher Nerv Syst 15 : 295-301, 2010
PubMed
2) 「慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン」作成委員会 編 : 慢性炎症性脱髄性多発根ニューロパチー・多巣性運動ニューロパチー診療ガイドライン 2013. 南江堂, 2013
 
3) Van Asseldonk JT, Franssen H, Van den Berg-Vos RM et al : Multifocal motor neuropathy. Lancet Neurol 4 : 309-319, 2005
PubMed
4) Miyashiro A, Matsui N, Shimatani Y et al : Are multifocal motor neuropathy patients underdiagnosed? An epidemiological survey in Japan. Muscle and Nerve 49 : 357-361, 2014
PubMed
P.305 掲載の参考文献
1) Lunn MP, Nobile-Orazio E : Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 10 : Cd002827, 2016
PubMed
2) 日本骨髄腫学会 編 : 多発性骨髄腫の診療指針 第5版. 文光堂, 2020
 
3) Suichi T, Misawa S, Sato Y et al : Proposal of new clinical diagnostic criteria for POEMS syndrome. J Neurol Neurosurg Psychiatry 90 : 133-137, 2019
PubMed
4) Misawa S, Sato Y, Katayama K et al : Safety and efficacy of thalidomide in patients with POEMS syndrome : a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 15 : 1129-1137, 2016
PubMed
5) Jaccard A, Moreau P, Leblond V et al : High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. E Engle J Med 357 : 1083-1093, 2007
 
P.309 掲載の参考文献
1) Kurihara S, Adachi Y, Wada K et al : An epidemiological genetic study of Charcot-Marie-Tooth disease in western Japan. Neuroepimiology 21 : 246-250, 2002
PubMed
2) 大矢寧 : Charcot-Marie-Tooth病. "EBMに基づく脳神経疾患の基本治療指針" 田村晃, 松谷雅生, 清水輝夫 他編, メジカルレビュー社, pp464-466, 2006
 
3) 中川正法 : シャルコー・マリー・トゥース病の遺伝子診断の進歩と治療戦略. 日本内科学会雑誌 105 : 1855-1862, 2016
 
4) 難病情報センター : シャルコー・マリー・トゥース病 概要・診断基準 https://www.nanbyou.or.jp/wp-content/uploads/upload_files/File/010-201704-kijyun.pdf (2021年3月5日閲覧)
 
5) 石山昭彦 : 遺伝性ニューロパチー. 脳と発達 51 : 184-189, 2019
Medical*Online
6) 高嶋博 : 遺伝性ニューロパチーの分子遺伝学. 臨床神経学 46 : 1-18, 2006
 
7) 中島孝 : 神経・筋難病患者が装着するロボットスーツHALの医学的応用に向けた進捗, 期待される臨床効果. 保健医療科学 60 : 130-137, 2011
 
P.315 掲載の参考文献
1) Oshima T, Kawahara S, Ueda M et al : Changes in pathological and biochemical findings of systemic tissue sites in familial amyloid polyneuropathy more than 10 years after liver transplantation. J Neurol Neurosurg Psychiatry 85 : 740-746, 2014
PubMed
2) Adams D, Gonzalez-Duarte A, O'Riordan WD et al : Patisiran, a RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379 : 11-21, 2018
PubMed
3) Coelho T, Maia LF, Martins da Silva A et al : Tafamidis for transthyretin familial amyloid polyneuropathy : a randomized, controlled trial. Neurology 79 : 785-792, 2012
PubMed
4) Maurer MS, Schwartz JH, Gundapaneni B et al : Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379 : 1007-1016, 2018
PubMed
P.319 掲載の参考文献
1) Practice parameter for electrodiagnostic studies in carpal tunnel syndrome : summary statement. Muscle Nerve 25 : 918-922, 2002
PubMed
2) 日本神経治療学会 : 標準的神経治療 : 手根管症候群. 神経治療学 25 : 63-84, 2008
Medical*Online
3) Ochoa J et al : Changes produced by a pneu-matic torniquet. In : Desmedt JE ed. New developments in EMG and clinical neuro-physiology. Basel : Karger 2 : 174-180, 1973
 
4) 幸原伸夫 : 手根管症候群の診断. Brain and Nerve 59 : 1229-1238, 2007
 
P.327 掲載の参考文献
1) Jennette JC, Falk RJ, Bacon PA et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013
 
2) Vrancken AF, Said G : Vasculitic neuropathy. Handbook Clin Neurol 115 : 463-83, 2013
 
3) Collins MP, Dyck PJ, Gronseth GS et al : Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy : executive summary. J Peripher Nerv Syst 15 : 176-184, 2010
 
4) Hadden RDM, Collins MP, Zivkovic SA et al : Vasculitic peripheral neuropathy : Case definition and guidelines for collection, analysis, and presentation of immunisation safety data. Vaccine 35 : 1567-1578, 2017
PubMed
5) 日本循環器学会, 日本医学放射線学会, 日本眼科学会 他 : 血管炎症候群の診療ガイドライン (2017年改定版) https://www.j-circ.or.jp/old/guideline/pdf/JCS2017_isobe_h.pdf (2021年3月8日閲覧)
 
6) 厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 難治性血管炎に関する調査研究班 他編 : ANCA関連血管炎診療ガイドライン 2017 https://minds.jcqhc.or.jp/docs/minds/ANCA-associated-vasculitis/ANCA-associated-vasculitis.pdf (2021年3月8日閲覧)
 
P.333 掲載の参考文献
1) Pratt RW, Weimer LH : Medication and toxin-induced peripheral neuropathy. Semin Neurology 25 : 204-216, 2005
PubMed
2) 横山和仁 : 有害環境因子による末梢神経障害. Peripheral Nerve 13 : 11-15, 2002
 
3) Malik B, Stillman M : Chemotherapy-induces peripheral neuropathy. Curr Neurol Neuosci Reports 8 : 56-65, 2008
 
4) 橋本黎, 上田健博, 辻佑木生 他 : ステロイド治療を併用して改善した免疫チェックポイント阻害薬によるギラン・バレー症候群様急性炎症性脱髄性ポリニューロパチーの1例. 臨床神経, 2020 (in press)
 
5) Brahmer JR, Lacchetti C, Schneider BJ et al : Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36 : 1714-1768, 2018
 
P.337 掲載の参考文献
1) Sweeney CJ, Gilden DH : Ramsay Hunt syndrome. J Neurol Neurosurg Psychiatry 71 : 149-154, 2001
PubMed
2) Tomita H, Hayakawa W : Varicella-Zoster virus in idiopathic facial palsy. Arch Otolaryngol 95 : 364-368, 1972
PubMed
3) Furuta Y, Takasu T, Fukuda S et al : Detection of varicella-zoster virus DNA in human geniculate ganglia by polymerase chain reaction. J Infect Dis 166 : 1157-1159, 1992
PubMed
4) 柳原尚明, 西村宏子, 陌間啓芳 他 : 顔面神経麻痺程度の判定基準に関する検討. 日耳鼻会報 8 : 799-805, 1977
 
5) House JW, Brackmann DE : Facial nerve grading system. Otolaryngol Head Neck Surg 93 : 146-147, 1985
PubMed
6) Sullivan FM, Swan IR, Donnan PT et al : Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med 357 : 1598-1607, 2007
 
7) May M : Nerve excitability test in facial palsy : limitations in its use, based on a study of 130 cases. Laryngoscope 82 : 2122-2128, 1972
PubMed
8) Campbell ED, HICKEY RP, NIXON KH et al : Value of nerve-excitability measurements in prognosis of facial palsy. Br Med J 2 : 7-10, 1962
PubMed
9) 青柳優 : 顔面神経麻痺の電気的診断法. 耳鼻臨床 95 : 985-995, 2002
 
10) 村上信五 : ウイルス性顔面神経麻痺-病態と後遺症克服のための新たな治療-. 日耳鼻会報 118 : 368-374, 2015
 
11) Fisch U : Surgery for Bell's palsy. Arch Otolaryngol 107 : 1-11, 1981
PubMed
P.343 掲載の参考文献
1) Schweickert WD, Hall J : ICU-acquired weakness. Chest 131 : 1541-1549, 2007
PubMed
2) Stevens RD, Marshall SA, Cornblath DR et al : A frame- work for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med 37 : S299-308, 2009
 
3) Bolton CF : Neuromuscular manifestations of critical illness. Muscle Nerve. 32 : 140-163, 2005
PubMed
4) Lacomis D, Zochodne DW, Bird SJ : Critical illness myopathy. Muscle Nerve 23 : 1767-1772, 2000
 
5) Hermans G, De Jonghe B, Bruyninckx F et al : Interventions for preventing critical illness polyneuropathy and critical illness myopathy. Cochrane Database Syst Rev 1 : CD006832, 2014
PubMed
6) Doiron KA, Hoffmann TC, Beller EM : Early intervention (mobilization or active exercise) for critically ill adults in the intensive care unit Cochrane Database Syst Rev 3 : CD010754, 2018
PubMed
7) Kou K, Momosaki R, Miyazaki S et al : Impact of nutrition therapy and rehabilitation on acute and critical illness : a systematic review. J UOEH 41 : 303-315, 2019
PubMed
8) Harvey MA, Davidson JE : Postintensive care syndrome : right care, right now...and later. Crit Care Med 44 : 381-385, 2016
 
9) Koch S, Spuler S, Deja M et al : Critical illness myopathy is frequent : accompanying neuropathy protracts ICU discharge. J Neurol Neurosurg Psychiatry 82 : 287-293, 2011
PubMed
10) 畑中裕己 : ICUAWの診断. 臨床神経生理学 48 : 128-135, 2020
Medical*Online
11) Hatanaka Y, Miyaji Y, Kawamura Y et al : Clinical application of the measurement of muscle fiber conduction velocity using direct muscle stimulation for critical illness myopathy (CIM). Clinical Neurophysiol 12 : e168, 2017
 
12) Vander Berghe G, Wilmer A, Milants I et al : Intensitve insulin therapy in mixed medical/surgical intensive care units : benefit versus harm. Diabetes 55 : 3151-3159, 2006
 
13) NICE-SUGAR Study Investigators, Finfer D, Chirttock DR et al : Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360 : 1283-1297, 2009
 
14) Brunner R, Rinner W, Haberler C et al : Early treatment with IgM-enriched intravenous immunoglobulin does not mitigate critical illness polyneuropathy and/or myopathy in patients with multiple organ failure and SIRS/sepsis : a prospective, randomized, placebo-controlled, double-blinded trial. Critical Care 17 : R213, 2013
PubMed
15) Zayed Y. Kheiri B, Barbarawi M et al : Effects of neuromuscular electrical stimulation in critically ill patients : a systematic review and metaanalysis of randomised controlled trials Aust Crit Care 33 : 203-210, 2020
PubMed
P.350 掲載の参考文献
1) 池田修一, 厚生労働科学研究費補助金慢性の痛み対策研究事業難治性神経因性疼痛の基礎疾患の解明と診断・治療精度を向上させるための研究班 : 神経痛性筋萎縮症 臨床診断ガイドライン. 末梢神経 28 : 114-115, 2017
 
2) Gstoettner C, Mayer JA, Rassam S et al : Neuralgic amyotrophy : a paradigm shift in diagnosis and treatment. J Neurol Neurosurg Psychiatry 91 : 879-888, 2020
PubMed
3) Parsonage MJ, Turner JW : Neuralgic amyotrophy ; the shoulder-girdle syndrome. Lancet 1 : 973-978, 1948
PubMed
4) Waxman SG : The flexion-adduction sign in neuralgic amyotrophy. Neurology 29 : 1301-1304, 1979
PubMed
5) van Alfen N, van Engelen BG : The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain 129 : 438-450, 2006
PubMed
6) 東原真奈, 園生雅弘, 今福一郎 他 : 神経痛性筋萎縮症-本邦における臨床像についての検討-. 末梢神経 26 : 203-205, 2015
Medical*Online
7) Van Eijk JJ, Groothuis JT, Van Alfen N : Neuralgic amyotrophy : an update on diagnosis, pathophysiology, and treatment. Muscle Nerve 53 : 337-350, 2016
PubMed
8) 森口幸太, 宮本勝一, 楠進 : NAの治療-IVIg療法を中心に. 脊椎脊髄ジャーナル 31 : 503-506, 2018
 
9) 園生雅弘 : 腕神経叢障害. 臨床神経生理学 41 : 157-163, 2013
Medical*Online
10) 東原真奈, 園生雅弘 : 神経痛性筋萎縮症の電気診断. 脊椎脊髄ジャーナル 31 : 485-490, 2018
 
11) 越智健介 : 特発性前骨間神経麻痺と特発性後骨間神経麻痺. 脊椎脊髄ジャーナル 31 : 507-518, 2018
 
12) 吉田剛, 末吉健志, 諏訪園秀吾 : NAの画像診断 特にMR neurographyによる鑑別診断. 脊椎脊髄ジャーナル 31 : 491-498, 2018
 
13) 野寺裕之, 高松直子 : NAの超音波診断. 脊椎脊髄ジャーナル 31 : 499-502, 2018
 
14) van Alfen N, van Engelen BG, Hughes RA : Treatment for idiopathic and hereditary neuralgic amyotrophy (brachial neuritis). Cochrane Database Syst Rev : CD006976, 2009
PubMed
15) 川村眞弓, 石川奈々, 坂本光弘 : 神経痛性筋萎縮症 自験例89例の解析. 末梢神経 25 : 77-83, 2014
Medical*Online
16) Naito KS, Fukushima K, Suzuki S et al : Intravenous immunoglobulin (IVIg) with methylprednisolone pulse therapy for motor impairment of neuralgic amyotrophy : clinical observations in 10 cases. Intern Med 51 : 1493-1500, 2012
PubMed

10. 筋疾患

P.357 掲載の参考文献
1) 厚生労働科学研究費補助金難治性疾患等政策研究事業自己免疫疾患に関する調査研究班 編 : 多発性筋炎・皮膚筋炎診療ガイドライン (2020年暫定版)
 
2) van der Meulen MF, Bronner IM, Hoogendijk JE et al : Polymyositis : an overdiagnosed entity. Neurology 61 : 316-321, 2003
PubMed
3) Hervier B, Uzunhan Y : Inflammatory myopathy-related interstitial lung disease : from pathophysiology to treatment. Front Med (Lausanne) 6 : 326, 2020
PubMed
4) Uruha A, Allenbach Y, Charuel JL et al : Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis. Neuropathol Appl Neurobiol 45 : 513-522, 2019
PubMed
5) Lundberg IE, Tjarnlund A, Bottai M et al : 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76 : 1955-1964, 2017
PubMed
6) Schmidt J : Current classification and management of inflammatory myopathies. J Neuromuscul Dis 5 : 109-129, 2018
PubMed
P.361 掲載の参考文献
1) 日本神経学会 監 : 重症筋無力症診療ガイドライン 2014, 南江堂, 2014
 
2) Oyama M, Okada K, Masuda M et al : Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis. Ther Adv Neurol Disord 13 : 1756286420904207, 2020
PubMed
3) Suzuki S, Ishikawa N, Konoeda F et al : Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89 : 1127-1134, 2017
PubMed
P.367 掲載の参考文献
1) 厚生労働省難治性疾患 (神経免疫疾患) 政策および実用化研究班 : 重症筋無力症ならびにランバート・イートン筋無力症候群の全国疫学調査 一次調査による患者数推計. 厚生労働省神経免疫疾患のエビデンスによる診断基準・重症度分類・ガイドラインの妥当性と患者QOL の検証. 平成30年度合同班会議抄録集, p12-13, 2019
 
2) Kesner VG, Oh SJ, Dimachkie MM et al. Lambert-Eaton Myasthenic Syndrome. Neurol Clin 36 : 379-394, 2018
PubMed
3) 北之園寛子, 白石裕一, 本村政勝 : 【Antibody Update 2018】P/Q型カルシウムチャネル抗体とランバート・イートン筋無力症候群 BRAIN and NERVE 70 : 341-355, 2018
 
4) Nakao YK, Motomura M, Fukudome T et al : Seronegative Lambert-Eaton myasthenic syndrome : study of 110 Japanese patients. Neurology 59 : 1773-1775, 2002
PubMed
5) O'Neill JH, Murray NM, Newsom-Davis J : The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 111 : 577-596, 1988
PubMed
6) Titulaer MJ, Wirtz PW, Kuks JB et al : The Lambert-Eaton myasthenic syndrome 1988-2008 : a clinical picture in 97 patients. J Neuroimmunol 201-202 : 153-158, 2008
 
7) Abenroth DC, Smith AG, Greenlee JE et al : Lambert-Eaton myasthenic syndrome : epidemiology and therapeutic response in the national veterans affairs population. Muscle Nerve 56 : 421-426, 2017
PubMed
8) Liu Y, Xi J, Zhou L et al : Clinical characteristics and long term follow-up of Lambert-Eaton myasthenia syndrome in patients with and without small cell lung cancer. J Clin Neurosci 65 : 41-45, 2019
 
9) Morimoto M, Osaki T, Nagara Y et al : Thymoma with Lambert-Eaton myasthenic syndrome. Ann Thorac Surg 89 : 2001-2003, 2010
PubMed
10) Oyaizu T, Okada Y, Sagawa M et al : Lambert-Eaton myasthenic syndrome associated with an anterior mediastinal small cell carcinoma. J Thorac Cardiovasc Surg 121 : 1005-1006, 2001
PubMed
11) Siau RT, Morris A, Karoo RO : Surgery results in complete cure of Lambert-Eaton myasthenic syndrome in a patient with metastatic Merkel cell carcinoma. J Plast Reconstr Aesthet Surg 67 : e162-164, 2014
 
12) Ferlito A, Rinaldo A, Bishop JA et al : Paraneoplastic syndromes in patients with laryngeal neuroendocrine carcinomas : clinical manifestations and prognostic significance. Eur Arch Otorhinolaryngol 273 : 533-536, 2016
PubMed
13) Nalbantoglu M, Kose L, Uzun N et al : Lambert-Eaton myasthenic syndrome associated with thymic neuroendocrine carcinoma. Muscle Nerve 51 : 936-938, 2015
PubMed
14) Iyer JG, Parvathaneni K, Bhatia S et al : Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC) : a case series of 8 patients highlighting different clinical manifestations. J Am Acad Dermatol 75 : 541-547, 2016
PubMed
15) Pavolucci L, Giannini G, Giannoccaro MP et al : Paraneoplastic cerebellar degeneration and lambert-eaton myasthenia in a patient with merkel cell carcinoma and voltage-gated calcium channel antibodies. Muscle Nerve 56 : 998-1000, 2017
 
16) Takasugi J, Shimamura M, Koda T et al : A case of paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenic syndrome associated with neuroendocrine carcinoma of the oropharynx. Intern Med 57 : 587-590, 2017
PubMed
17) Fukuda T, Motomura M, Nakao Y et al : Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 53 : 21-28, 2003.
PubMed
18) Shimizu F, Takeshita Y, Sano Y et al : GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome. Brain 142 : 2253-2264, 2019
PubMed
19) 松本理器, 本村政勝, 吉村俊朗 他 : Lambert-Eaton筋無力症候群型の神経筋伝達障害を示した重症筋無力症 血清自己抗体と神経筋接合部生検の有用性. 臨床神経学 39 : 531-537, 1999
 
20) Matsumoto H, Ohtomo G, Akahori T et al : Lambert-Eaton myasthenic syndrome with anti-acetylcholine receptor antibody and anterior mediastinal tumor. J Gen Fam Med 18 : 282-284, 2017
PubMed
21) Lorenzoni PJ, Scola RH, Kay CSK et al : How to spot congenital myasthenic syndromes resembling the Lambert-Eaton myasthenic syndrome? a brief review of clinical, electrophysiological, and genetics features. Neuromolecular Med 20 : 205-214, 2018
PubMed
22) Maddison P, Newsom-Davis J, Mills KR : Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 65 : 213-217, 1998
PubMed
23) Oh SJ, Kurokawa K, Claussen GC et al : Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 32 : 515-520, 2005
PubMed
24) Hatanaka Y, Oh SJ : Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome. Muscle Nerve 37 : 572-575, 2008
PubMed
25) Chiou-Tan FY, Gilchrist JM : Repetitive nerve stimulation and single-fiber electromyography in the evaluation of patients with suspected myasthenia gravis or Lambert-Eaton mtasthenic syndrome : review of recent literature. Muscle Nerve 52 : 455-462, 2015
PubMed
26) Motomura M, Johnston I, Lang B et al : An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurolosurg Psychiatry 58 : 85-87, 1995
 
27) Lennon VA, Kryzer TJ, Griesmann GE et al : Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 332 : 1467-1474, 1995
PubMed
28) Zalewski NL, Lennon VA, Lachance DH et al : P/Q- and N-type calcium-channel antibodies : oncological, neurological, and serological accompaniments. Muscle Nerve 54 : 220-227, 2016
 
29) Newsom-Davis J : A treatment algorithm for Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 841 : 817-822, 1998
PubMed
30) Maddison P, Newsom-Davis J : Treatment for Lambert-Eaton myasthenic syndrome. THE COCHRANE COLLABORATION, 2008
 
31) Skeie GO, Apostolski S, Evoli A et al : Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 17 : 893-902, 2010
PubMed
32) Maddison P, Gozzard P, Grainge MJ et al : Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 88 : 1334-1339, 2017
PubMed
P.373 掲載の参考文献
1) 栗原照幸 : 高カリウム血性周期性四肢麻痺-病態生理, 分子遺伝学と鑑別診断-. 脳神経 49 : 1059-1066, 1997
 
2) 栗原照幸 : 高カリウム血性周期性四肢麻痺と先天性パラミオトニー. Clin Neuroscience 18 : 63-66, 2000
 
3) Brooks JE : Hyperkalemic periodic paralysis. Intracellular electromyographic studies. Arch Neurol 20 : 13-18, 1969
PubMed
4) Kalita J, Goyal G, Bhol SK et al : Comparative study of thyrotoxic periodic paralysis from idiopathic periodic paralysis : An experience from India. Ann Indian Acad Neurol 15 : 186-190, 2012
 
5) Bilha S, Mitu O, Teodoriu L et al : Thyrotoxic periodic paralysis-A misleading challenge in the emergency department. Diagnostics (Basel) 10 : 316-327, 2020
PubMed
6) Tassone H, Moulin A, Henderson SO : The pitfalls of potassium replacement in thyrotoxic periodic paralysis : a case report and review of the literature. J Emerg Med 26 : 157-161, 2004
PubMed
7) 小林光太郎, 根本真人, 片塩仁 他 : 甲状腺機能亢進症を伴う低カリウム性周期性四肢麻痺症例のカリウム補充療法. 日集中医誌 15 : 239-240, 2008
 
P.379 掲載の参考文献
1) 「デュシェンヌ型筋ジストロフィー診療ガイドライン」作成委員会 編 : デュシェンヌ型筋ジストロフィー診療ガイドライン 2014. 南江堂, 2014
 
2) Birnkrant DJ, Bushby K, Bann CM et al : Diagnosis and management of Duchenne muscular dystrophy, part 1 : diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 17 : 251-267, 2018
PubMed
3) Birnkrant DJ, Bushby K, Bann CM et al : Diagnosis and management of Duchenne muscular dystrophy, part 2 : respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 17 : 347-361, 2018.
PubMed
P.385 掲載の参考文献
1) Matsumura T, Kimura T, Yosuke Kokunai Y et al : Simple questionnaire for screening patients with myotonic dystrophy type 1. Neurology and Clinical Neuroscience 2 (4) : 97-103, 2014
 
2) Ashizawa T, Gagnon C, Groh WJ et al : Consensus-based care recommendations for adults with myotonic dystrophy type 1. Neurol Clin Pract 8 (6) : 507-520, 2018
PubMed
3) 日本神経学会 監 : 筋強直性ジストロフィー診療ガイドライン 2020. 南江堂, 2020
 
P.394 掲載の参考文献
1) Parikh S, Goldstein A, Koenig MK et al : Diagnosis and management of mitochondrial disease : a consensus statement from the Mitochondrial Medicine Society. Genet Med 17 : 689-701, 2015
 
2) Parikh S, Goldstein A, Karaa A et al : Patient care standards for primary mitochondrial disease : a consensus statement from the Mitochondrial Medicine Society. Genet Med 19, 2017
 
3) 日本ミトコンドリア学会 編 : ミトコンドリア病診療マニュアル 2017. 診断と治療社, 2016
 
4) Ng YS, Bindoff LA, Gorman GS et al : Consensus-based statements for the management of mitochondrial stroke-like episodes [version 1 ; peer review : 2 approved]. Wellcome Open Res 4 : 201, 2019
 
5) DiMauro S, Schon EA : Mitochondrial respiratory-chain diseases. N Engl J Med 348 : 2656-2668, 2003
PubMed
6) Iizuka T, Sakai F, Suzuki N et al : Neuronal hyperexcitability in stroke-like episodes of MELAS syndrome. Neurology 59 : 816-824, 2002
PubMed
7) Koga Y, Povalko N, Nishioka J et al : MELAS and L-arginine therapy : pathophysiology of stroke-like episodes. Ann N Y Acad Sci 1201 : 104-110, 2010
PubMed
8) Hongo Y, Kaneko J, Suga H et al : A cluster of disseminated small cortical lesions in MELAS : its distinctive clinical and neuroimaging features. J Neurol 266 : 1459-1472, 2019
PubMed
9) 村山圭, 小坂仁, 三牧正和 編 : ミトコンドリアと病気 (遺伝子 MOOK35). メデイカルドゥ, 2020
 
P.398 掲載の参考文献
1) Miller TM, Lazer RB : Muscle cramps. Muscle Nerve 32 : 431-442, 2005
 
2) 有村公良 : 内科学 (第九版). 杉本恒明, 矢崎義雄 編, 朝倉書店, 2007
 

11. 機能性疾患

P.403 掲載の参考文献
1) 日本頭痛学会・国際分類普及委員会 訳 : 国際頭痛分類 第2版 日本語版. 日本頭痛学会誌 31, 2004
 
2) 根来清 : 三叉神経痛と顔面痛. Medicina 11 : 1889-1891, 2006
 
3) Scrivani SJ, Mathew ES, Maciewicz RJ : Trigeminal neuralgia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100 : 527-538, 2005
 
4) 秋口一郎 : 三叉神経痛の第1選択は. EBM神経疾患の治療. 岡本幸市, 棚橋紀夫, 水澤英洋 編. 中外医学社, pp402-406, 2007
 
5) 加藤丈夫 : 神経痛 (三叉神経痛, 舌咽神経痛, 後頭神経痛) -ヘルペスによるものを含む. 山口徹, 北原光夫 編. 医学書院, pp643-645, 2004
 
P.411 掲載の参考文献
1) Headache Classification Committee of the International Headache Society : The Inter-national Classification of Headache Disorders 3rd edition (ICHD-II). Cephalalgia 38 : 1-211, 2018
 
2) 日本頭痛学会・国際頭痛分類普及委員会 訳 : 国際頭痛分類 第3版 新訂増補日本語版. 医学書院, 2018
 
3) 日本頭痛学会 編 : 慢性頭痛の診療ガイドライン 2013. 医学書院, 2013
 
P.415 掲載の参考文献
1) Thijs RD, Surges R, O'Brien TJ et al : Epilepsy in adults. Lancet 393 : 689-701, 2019
PubMed
2) Kanner AM, Ashman E, Gloss D et al : Practice guideline update summary : Efficacy and tolerability of the new antiepileptic drugs I : Treatment of new-onset epilepsy : Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 91 : 74-81, 2018
 
3) 「てんかん診療ガイドライン」作成委員会 編 : てんかん診療ガイドライン 2018. 医学書院, 2018
 

12. 感染性疾患

P.426 掲載の参考文献
1) 日本神経学会, 日本神経治療学会, 日本神経感染症学会 監修 : 細菌性髄膜炎診療ガイドライン 2014, 南江堂, 2015
 
2) Kamei S, Takasu T : Nationwide survey of the annual prevalence of viral and other neurological infections in Japanese inpatients. Internal Medicine 39 : 894-900, 2000
PubMed
3) 厚生労働科学研究費補助金, 新型インフルエンザ等新興・再興感染症研究事業 (H22-新興-一般-013) : 重症型のレンサ球菌・肺炎球菌感染症に対するサーベイランスの構築と病因解析, その診断・治療に関する研究 (研究代表 : 生方公子), 2012
 
4) Thigpen MC, Whitney CG, Messonnier NE et al : Bacterial meningitis in the United States, 1998-2007. N Engl J Med 364 : 2016-2025, 2011
PubMed
5) Kimura K, Suzuki S, Wachino J et al : First molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother 52 : 2890-2897, 2008
 
6) 庵原俊昭, 菅秀, 浅田和豊 他 : インフルエンザ菌b型 (Hib) ワクチンおよび7価肺炎球菌結合型ワクチン (PCV7) 導入が侵襲性細菌感染症に及ぼす効果について. IASR. 33 : 71-72, 2012
 
7) Chiba N, Morozumi M, Shouji M et al : Changes in capsule and drug Resistance of pneumococci after introduction of PCV7, Japan, 2010-2013. Emerg Infect Dis 20 : 1132-1139, 2014
PubMed
8) Tunkel AR : Bacterial meningitis. Lippincott Williams & Wilkins, 2001
 
9) Conly JM, Ronald AR : Cerebrospainal fluid as a diagnostic body fluid. Amer J Med 75 (1B) : 102-108, 1983
PubMed
10) van de Beek D, de Gans J, Spanjaard L et al : Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 351 : 1849-1859, 2004
PubMed
11) Thomson RB Jr, Bertram H : Laboratory diagnosis of central nervous system infections. Infect Dis Clin North Am 15 : 1047-1071, 2001
PubMed
12) Camargos PA, Almeida MS, Filho GL et al : Blood stained cerebrospinal fluid responsible for false positive reactions of latex particle agglutination test. J Clin Pathol 47 : 1116-1117, 1994
PubMed
13) Tarafdar K, Rao S, Recco RA et al : Lack of sensitivity of the latex agglutination test to detect bacterial antigen in the cerebrospinal fluid of patients with culture-negative meningitis. Clin Infect Dis 33 : 406-408, 2001
PubMed
14) Genne D, Siegrist HH, Lienhard R : Enhancing the etiologic diagnosis of community-acquired pneumonia in adults using the urinary antigen assay (Binax NOW). Int J Infect Dis 10 : 124-128, 2006
PubMed
15) Tunkel AR, Hartman BJ, Kaplan SL et al : Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39 : 1267-1284, 2004
PubMed
16) Gendrel D, Raymond J, Assicot M et al : Measurement of procalcitonin levels in children with bacterial or viral meningitis. Clin Infect Dis 24 : 1240-1242, 1997
 
17) Genton B, Berger JP : Cerebrospinal fluid lactate in 78 cases of adultmeningitis. Intensive Care Med 16 : 196-200, 1990
PubMed
18) Hasbun R, Abrahams J, Jekel J et al : Computed tomography of the head before lumbar puncture in adults with suspected meningitis. N Engl J Med 345 : 1727-1733, 2001
PubMed
19) 葛目大輔, 森本優子, 金星匡人 他 : 無菌性髄膜炎におけるjolt accentuation of headacheの意義. 臨床神経 59 : 596-599, 2019
 
P.431 掲載の参考文献
1) 「単純ヘルペス脳炎診療ガイドライン」作成委員会 編 : 単純ヘルペス脳炎診療ガイドライン 2017. 南江堂, 2017
 
2) 日本神経感染症学会 編 : ヘルペス脳炎-診療ガイドラインに基づく診断基準と治療指針-. 中山書店, 2006
 
3) 水澤英洋, 辻 省次 編 : 神経感染症を究める (アクチュアル 脳・神経疾患の臨床). 中山書店, 2014
 
P.437 掲載の参考文献
1) 日本結核病学会治療委員会 : 「結核医療の基準」の改訂-2018年. 結核 93 : 61-68, 2018
Medical*Online
2) 日本神経治療学会治療指針作成委員会 : 標準的神経治療 : 結核性髄膜炎. 神経治療 32 : 511-532, 2015
Medical*Online
3) 野崎博之 : 結核性髄膜炎. Clin Neurosci 33 : 1255-1258, 2015
 
4) 亀井聡 : 結核性髄膜炎. 日本神経救急学会雑誌 27 : 46-49, 2015
 
5) Jinkins JR, Gupta R, Chang KH et al : MR imaging of central nervous system tuberculosis. Radiol Clin North Am 33 : 771-786, 1995
PubMed
6) Denkinger CM, Schumacher SG, Boehme CC et al : Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis : a systemic review and meta-analysis. Eur Respir J 44 : 435-446, 2014
 
7) Marais S, Thwaites G, Schoeman JF et al : Tuberculous meningitis : a uniform case definition for use in clinical research. Lancet Infect Dis 10 : 803-812, 2010
PubMed
8) 野崎博之, 豊田丈夫, 高嶋修太郎 他 : 当院で経験した頭蓋内結核症6例のCT所見-特にその経過を中心にして-. 結核 67 : 383-392, 1992
 
P.441 掲載の参考文献
1) Garden GA : Microglia in human immuno-deficiency virus-associated neurodegeneration. Glia 40 : 240-251, 2002
 
2) Erdmann N et al : Glutamate production by HIV-1 infected human macrophage is blocked by the inhibition of glutaminase. J Neurochem 102 (2) : 539-549, 2007
PubMed
3) Simpson DM : Human immunodeficiency virus-associated dementia : Review of pathogenesis, prophylaxis, and treatment studies of zidovu-dine therapy. Clin Infect Dis 29 : 19-34, 1999
 
P.445 掲載の参考文献
1) 厚生労働省科学研究費補助金難治性疾患政策研究事業「プリオン病及び遅発性ウイルス感染症に関する調査研究班」, 厚生労働省行政推進調査事業費補助金難治性疾患等政策研究事業「プリオン病のサーベイランスと感染予防に関する調査研究班」編 : プリオン病診療ガイドライン 2020 http://prion.umin.jp/guideline/pdf/guideline_2020.pdf (2021年4月23日閲覧)
 
2) 厚生労働省行政推進調査事業費補助金難治性疾患等政策研究事業「プリオン病のサーベイランスと感染予防に関する調査研究班」, 日本神経学会 編 : プリオン病感染予防ガイドライン 2020 http://prion.umin.jp/guideline/pdf/cjd_2020v6.pdf (2021年4月23日閲覧)
 
3) Nozaki I, Hamaguchi T, Sanjo N et al : Prospective 10-year surveillance of human prion diseases in Japan. Brain 133 : 3043-3057, 2010
PubMed
4) Parchi P, Giese A, Capellari S et al : Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypicanalysis of 300 subjects. Ann Neurol 46 : 224-233, 1999
PubMed
5) Global Surveillance, Diagnosis and therapy of human transmissible spongiform encephalopathies. Report of a WHO consultation ; 9-11 February 1998 ; Geneva https://www.who.int/csr/resources/publications/bse/whoemczdi989.pdf#search=%27CJD+WHO+and+global+surveillance+1998%27 (2021年4月23日閲覧)
 

書評

最近チェックした商品履歴

Loading...